ALBERT

Description / Table of Contents: Introduction -- The major processes in the biological world -- Enzymes, conformational changes, energy, and molecular motors -- The cells -- Genome -- Regulation of gene expression and protein activity -- DNA replication, its fidelity, mutations, and repair -- Transduction of signals -- Multicellular organisms and their development -- Biological defense I. Protection from foreign nucleic acids -- Biological defense II. The immune system of vertebrates -- Pathogens -- Cancer -- Index.

Description / Table of Contents: 1. The Quest for Excellence and the Challenge of Gender Equality in Arbovirology: A Celebration of Women’s Contributions to the Field -- 2. Serendipity and Arboviruses -- 3. The Tapestry of Life: Weaving an Arbovirologist -- 4. Arbovirus and Viral Hemorrhagic Fevers Research Inception in Central and West Africa -- 5. From Bwamba to the Present: The Changing Forest of Arbovirology -- 6. Fighting Dengue, Chikungunya and Japanese Encephalitis -- 7. Chronicles of Hantaviruses: Foundations of Epidemiology and Ecology -- 8. Yellow Fever and Other Viruses in West Africa -- 9. The “Golden Age” of Arbovirology, 1950-1969 -- 10. Twenty-Seven Years of Field Studies on Dengue and Aedes Aegypti in Latin America -- 11. 50 Years of Medical Entomology: Miscellaneous Interesting Findings -- 12. Remembrances of Virology Past -- 13. An Overview of Arbovirology in São Paulo State, Southeastern Brazil: Highlighting the Virus Research Center in Ribeirão Preto City -- 14. An Unplanned Career in Arbovirology.

Description / Table of Contents: Malaria: Cellular Understanding of Disease -- Drug Resistance, Statistics and Patent Status -- Malaria: Current Treatment Options -- Polymeric Nanoparticles in Malaria -- Solid Lipid Nanoparticles in Malaria -- Dendrimers in Malaria -- Liposomes in Malaria -- Micro and Nano Emulsions in Malaria -- Nanosuspension in Malaria -- Alginate and Gelatin Nanoparticles in Malaria -- Niosomes in Malaria -- Metal Nanoparticles in Malaria -- Nanotechnology in Malaria Diagnosis -- Nanotechnology-based Vaccination -- Herbal Platforms in Malaria -- Surface-modified Drug Delivery Systems in Malaria,- Clinical Trials in Malaria -- Malaria-Overall Picture -- New Drugs in Synthesis Research for Malaria -- Disease Models In Malaria Research.

Description / Table of Contents: Global health and Tuberculosis past, present and Future -- Tuberculosis: cellular understanding of disease.-Metal nanoparticles in TB -- TB: current treatment options -- Polymeric nanoparticles in TB -- Solid lipid nanoparticles in TB -- Dendrimers in TB -- Liposomes in TB -- Micro, nano emulsions in TB -- Nano suspension in TB -- Alginate, gelatin nanoparticles in TB -- Niosome in TB -- Surface modified drug delivery systems in TB -- Clinical trials in TB -- Herbal platforms in TB.

Description / Table of Contents: Part I: Basic Science of Cerebellum and Ataxias -- Functional anatomy of the cerebellum -- Cerebellar physiology -- Cerebellar biochemistry/pharmacology -- Genetics of dominant ataxias -- Autosomal and X-linked degenerative ataxias: from genetics to promising therapeutics -- Seeking therapies for Spinocerebellar Ataxia: from gene silencing to systems-based approaches -- Ion Channel Genes and Ataxia -- Part II: Biomarkers and tools of trials -- How to Design a Therapeutic Trial in SCAs -- Therapy development for spinocerebellar ataxia: Rating Scales and Biomarkers -- Clinical rating scales for ataxia -- Scale for Ocular motor Disorders in Ataxia (SODA): Procedures and Basic Understanding -- Cerebellar learning in the prism adaptation task -- Blood and CSF biomarkers in autosomal dominant cerebellar ataxias -- Part III: Autosomal Dominant Cerebellar Ataxias -- Riluzole in progressive cerebellar ataxias -- ASOs against ATXN2 in preclinical and phase 1 trials -- Antisense oligonucleotide therapy against SCA3 -- Spinocerebellar ataxia type 7: From mechanistic pathways to therapeutic opportunities -- Experimental neurotransplantation for cerebellar ataxias -- Development of mesenchymal stem cells therapy for the treatment of polyglutamine SCA: from bench to bedside -- Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia -- Cerebellar Transcranial Magnetic Stimulation in Cerebellar Ataxias -- Physical therapy in Cerebellar Ataxia -- Part IV: Autosomal Recessive Cerebellar Ataxias -- Recent advances on therapeutic approaches for Friedreich’s Ataxia -- Therapeutic use of interferon gamma in Friedreich ataxia -- Metabolic treatments of cerebellar ataxia -- Clinical Trials in Fragile X-Associated Tremor/Ataxia Syndrome -- Part V: Sporadic Ataxias -- Therapeutic strategies in immune-mediated cerebellar ataxias -- Coenzyme Q10 in MSA -- State of the Art and History of Therapeutics in Ataxias.

Description / Table of Contents: Introduction-.What is a DMC?-. Is a DMC required?-. Who is On the DMC?-. What are the Legal and Ethical Aspects of DMC?-. How does the DMC work with SDAC and Sponsor and External Groups ? -- What Does a DMC Meeting Look Like -- What data is used for DMC outputs and who programs? -- What is Included in DMC Outputs? -- What does the DMC final DMC outputs look like and how is it delivered? -- What Types of Safety Outputs Does the DMC Receive? -- What types of efficacy outputs does the DMC receive? -- What types of other outputs does the DMC receive? -- What About In-Between DMC Meetings -- What types of formal interim analyses does the DMC review? -- What does the paperwork from meetings look like? -- How does the DMC assess risk-benefit for their decision making? -- What are some examples? -- Conclusions.

Description / Table of Contents: Introduction to Biomaterials -- Biodegradable Polymers -- Natural and semi-natural polymers -- Fundamentals and Biomedical Applications of Smart Hydrogels -- Engineering biomaterials for nucleic acid-based therapies -- Mechanics of Biomaterials for Regenerative Medicine -- Biomaterials for controlled drug delivery applications -- BIOMATERIALS APPLICATION: IMPLANTS -- Living Biomaterials -- Therapeutic Polymer Conjugates and their Characterization -- Biocompatibility of Polymers -- Sterilization techniques of biomaterials (implants and medical devices).

Description / Table of Contents: Part 1: General / Technical Aspects -- Chapter 1: In Situ Imaging Of Virus Infected Cells By Cryo-Electron Tomography: An Overview -- Chapter 2: Approaches To Evaluating Necroptosis In Virus Infected Cells -- Chapter 3: Apoptosis And Phagocytosis As Antiviral Mechanisms -- Chapter 4: The Art Of Viral Membrane Fusion And Penetration -- Chapter 5: Single Particle Tracking Of Virus Entry In Live Cells -- Chapter 6: Correlative Cryo-Imaging Using Soft X-Ray Tomography For The Study Of Virus Biology In Cells And Tissues -- Chapter 7: The Virus-Induced Cytopathic Effect -- Part 2: Specific Viruses -- Chapter 8: Human Papilloma Virus-Infected Cells -- Chapter 9: Defining The Assembleome Of The Respiratory Syncytial Virus -- Chapter 10: Japanese Encephalitis Virus Infected Cells -- Chapter 11: African Swine Fever Virus Host-Pathogen Interactions -- Chapter 12: Coronavirus And The Cytoskeleton Of Virus-Infected Cells -- Chapter 13: Viral Rna Is A Hub For Critical Host-Virus Interactions -- Chapter 14: Influenza A Virus: Cellular Entry -- Chapter 15: Human Endogenous Retroviruses In Diseases -- Chapter 16: Cholesterol And M2 Rendezvous In Budding And Scission Of Influenza A Virus.

Description / Table of Contents: Overview of Freeze Drying -- Characterization and Determination of Freeze Drying Properties of Frozen Formulations – Case Studies -- Beyond pH: Acid/base relationships in frozen and freeze-dried pharmaceuticals -- Concepts and Strategies in the Design of Formulation for Freeze Drying -- Formulation Design for Freeze Drying - Case studies of Stabilization of Proteins -- Challenges and Considerations in the Development of a High Protein Concentration Lyophilized Drug Product -- Freeze-drying of thermosensible pharmaceuticals with organic co-solvent + water formulations -- Primary container closure system selection for lyophilized drug products -- Vial Breakage During Lyophilization -- The Nucleation of Ice -- Stresses, Stabilization, and Recent Insights in Freezing of Biologics -- Lyophilization Process Understanding and Scale-up using ab initio Vial Heat Transfer Modeling -- Secondary drying: Challenges and Considerations -- Design and Process Considerations in Spray Freeze Drying -- LyoPRONTO: Deterministic and Probabilistic Modeling. Tutorial and Case Study -- Utilizing Solid-State NMR Spectroscopy to Assess Properties of Lyophilized Formulations -- Design of Moisture Studies for a Lyophilized Product -- Laser-Based Headspace Moisture Analysis for Rapid Nondestructive Moisture Determination of Lyophilized Products -- Application of PAT in Real-time Monitoring and Controlling of Lyophilization Process -- Process Analytical Technology (PAT) for Lyophilization Process Monitoring and End Point Detection -- Advances in Process Analytical Technology – A Small Scale Freeze-Dryer for Process Analysis, Optimization, and Transfer -- Overview of Heat and Mass Transfer Modeling in Lyophilization to Create Design Spaces and Improve Process Analytical Tool (PAT) Capability -- Application of QbD elements in the Development and Manufacturing of a Lyophilized product -- Characterization of Freeze Dryer -- Scale-up and Technology Transfer of a Lyophilization Process -- Lyophilization Validation: Process Design and Modeling -- Lyophilization Validation: Process Qualification and Continued Process Verification -- Homogeneity Assessment of Lyohilized Biological Drug Products During Process Performance Qualification -- Informed Manufacturing through the use of Big Data Analytics for Freeze Drying Process & Equipment -- Multivariate Analysis for Process Understanding, Continuous Process Verification and Condition Monitoring of Lyophilization Processes -- Lyophilized Drug Product Cake Appearance: What Is Acceptable?.

Description / Table of Contents: 1. Conducting polymers as drug release systems -- 2. Electrospinning for drug delivery applications -- 3. Melt-electrospinning and electrowriting for pharmaceutical and biomedical applications -- 4. Pharmaceutical Spray Drying -- 5. Vat photopolymerization 3D printing for drug delivery applications -- 6. Semi-solid extrusion 3D printing for the development of dosage forms for special patient groups -- 7. Binder-Jetting Powder bed 3D‐printing for the fabrication of drug delivery systems -- 8. 3D printing for localized cancer therapy -- 9. 4D Printing in Pharmaceutics & Biomedical Applications -- 10. Lithography in Drug-Delivery -- 11. Micro-moulding and its application to drug delivery -- 12. Supercritical Fluids: A Promising Technique in Pharmaceutics -- 13. Microfluidics as a tool for the synthesis of advanced drug delivery systems -- 14. Nanofluidic Technologies for Drug Screening and Drug Delivery -- 15. Nanoparticles at the stage of clinical trials -- 16. Nasal drug delivery systems for the treatment of diseases of the central nervous system and tuberculosis -- 17. Regulatory aspects and barriers in using ground-breaking technologies. .

Description / Table of Contents: New drugs in synthesis research for Malaria -- New drugs in synthesis research for TB -- New drugs in synthesis viral -- Nanotechnology in Malaria diagnosis -- Nanotechnology in TB diagnosis -- Nanotechnology based vaccination Malaria -- Nanotechnology based vaccination TB -- Disease models in Malaria research -- Disease models in TB research -- Disease models in Viral research -- Viral diseases- cellular understanding of disease : Vaccine development -- Pneumonia- infection -- bacterial pnuemonia -- Lipid based DDS in pneumonia -- hepatitis -- Recent Developments in the Treatment of Bacterial Meningitis -- Bacterial Urinary Tract Infections -- E.coli.

Description / Table of Contents: Varicella-zoster Virus - Genetics, Molecular Evolution, and Recombination -- The structures and functions of VZV glycoproteins -- Modulation of apoptosis and cell death pathways by Varicella zoster virus -- Modulation of host cell signaling pathways by varicella-zoster virus -- Modulation of MHC and MHC-like molecules by Varicella Zoster Virus -- Varicella Zoster Virus Neuronal Persistence and Reactivation modeled in-vitro -- Humanized Severe Combined Immunodeficient (SCID) Mouse Models for Varicella-Zoster Virus Pathogenesis -- Simian Varicella Virus: Molecular Virology and mechanisms of pathogenesis -- A guide to preclinical models of zoster-associated pain and postherpetic neuralgia -- Immune Responses to Varicella-Zoster Virus Vaccines -- Common features between stroke following varicella in children and stroke following herpes zoster in adults.

Description / Table of Contents: Chapter 1: Bioprocessing and analytical development for virus-based therapeutics -- Chapter 2: Viral Vector Upstream Processing and Clarification -- Chapter 3: Upstream processing of viral therapeutics: From host cell expansion to virus production -- Chapter 4: Leveraging virus biology and host genetic conflicts for cell line development and engineering for virus-based therapeutics -- Chapter 5: Overview of Current Downstream Processing for Modern Viral Vectors -- Chapter 6: Filtration Principles and Techniques for Bioprocessing of Viral Vector–Based Therapeutics -- Chapter 7: Chromatographic purification of viruses: State of the art and current trends -- Chapter 8: Purifying Viral Vectors - A Review of Chromatography Solutions -- Chapter 9: Particle analytics - Comparative approaches for analysis of viral vectors -- Chapter 10: Phase-Appropriate Potency Assay Development for AAV-based Gene Therapy Products -- Chapter 11: Quantification of virus infectivity – the key assay for the development of viral therapeutics -- Chapter 12: Product-related impurities in therapeutic virus bioprocessing -- Chapter 13: Process Analytical Technologies (PAT) and Quality by Design (QbD) for bioprocessing of virus-based therapeutics -- Chapter 14: Methods and practical considerations in imaging viral therapeutics -- Chapter 15: Application of NMR Spectroscopy in Viral Assembly Characterization -- Chapter 16: Improved Production Strategies for Oncolytic Measles Viruses as a Therapeutic Cancer Treatment -- Chapter 17: Recent Advancements and Challenges in Recombinant Expression for Commercial Production of Virus Like Particles (VLPs) -- Chapter 18: Oncolytic viruses and viral gene therapy vectors: Principles of safety.

Description / Table of Contents: Theoretical analysis of the evolution of viral populations in sequence space, and empirical fitness landscapes -- Self-organized maps to derive fitness landscapes from deep sequencing data -- Mutations to overcome viral resistance in plants -- The role of recombination in the generation of new begomovirus phenotypes -- Plant virus adaptation to new hosts -- Viral fitness, host interactions, and resistance to antiviral agents -- Viral fitness and evolution of hepatitis C virus -- Population dynamics and fitness variations of hemorrhagic RNA viruses -- Coronavirus genome sequences, variation, and disease implications -- Epilogue: viral populations from a theoretical and experimental perspective.

Description / Table of Contents: 50 years of Lassa fever research -- Lassa Virus Genetics -- Ecology of Lassa virus -- Epidemiology of Lassa Fever -- Lassa virus countermeasures -- Lassa virus structural biology and replication -- Lassa Fever Natural History and Clinical Management.

Description / Table of Contents: Nanocarriers for delivery of peptide antibiotics -- NANOMEDICINES FOR THE PULMONARY DELIVERY OF ANTIBIOTICS -- Inhalable nanomedicines for the treatment of pulmonary aspergillosis -- Nanomedicines for the treatment of systemic candidiasis -- Nanomedicine for the treatment of vaginal candidiasis -- Nanomedicines for the treatment of veterinary parasitic infections -- Role of Nanotechnology Against Malaria: Current Perspectives and Strategies -- NANOMEDICINES FOR THE TREATMENT OF TRYPANOSOMIASIS -- Nanomedicines to improve oral delivery of antiretroviral drugs -- Nano-Adjuvants -- Nanoscale Vaccines for Influenza -- Nano-scale vaccines for the prevention of hepatitis B virus infection -- Nanoscale Vaccines for the Prevention of COVID-19.

Description / Table of Contents: Chapter 1: The world of microorganisms -- Chapter 2: The dawn of microbiology -- Chapter 3: Communication between microorganisms -- Chapter 4: Microbial communities -- Chapter 5: Gene transfer -- Chapter 6: Multidrug resistant bacteria -- Chapter 7: Synthetic biology in microbiology -- Chapter 8: Artificial intelligence in microbiology -- Chapter 9: Emerging and zoonotic diseases -- Chapter 10: COVID-19 -- Chapter 11: Future pandemics -- Chapter 12: Into a brighter future.

Description / Table of Contents: The world in flux – the Columbian Exchange D. Domenici -- Glimpses into the past: new world contributions towards understanding the basic etiology, pathobiology & treatment of rabies, Drishya Kurup et al -- The Diversity, Evolution and Emergence of Rabies Virus in the Americas, Edward C. Holmes & Erin H. Harvey -- The ecological range and principles of wildlife rabies virus perpetuation in the Americas, Amy T. Gilbert -- Historical Laboratory Contributions Supporting Rabies Diagnosis and Disease Prevention and Control in the Americas, Susan A. Nadin-Davis, et al -- Progression from nerve tissue vaccines to recombinant biologics, H. Ertl -- Wildlife Rabies Management in the New World: Prevention, Control and Elimination in Mesocarnivores, R. Chipman et al -- Management of vampire bats and rabies: past, present, and future, Tonie Rocke & Daniel Streicker -- Conflicting Perspectives on a Rabies Outbreak in a Venezuelan Rainforest, 2007-2008, C. Briggs -- Rabies, Medicine, and Culture: Dogs, Disease, and Urban Life in the United States, 1840-1920, Jessica Wang -- Historical disparities in health: rabies surveillance, risk factors and prevention, Amira Roess et al -- The Health Economics of Rabies in the Americas: An Historical Summary and a Synthesis of the Literature, S.A. Shwiff -- Towards the elimination of canine rabies in the americas: governance of a regional program, M. Vigilato et al -- Musing Over Non-technical Criticalities of Rabies Prevention and Control in the Americas, Victor J. Del Rio Vilas & Gilberto Montibeller.

Description / Table of Contents: 1. Implications of renin-angiotensin system in health and disease -- 2. Renin angiotensin system and aging -- 3. The interplay of the renin-angiotensin system and solid organ transplantation -- 4. Correlation between renin angiotensin system and infectious disease -- 5. Emerging contributions of endocrine pathophysiology in virus-related infectious disease -- 6. Understanding the renin-angiotensin system in coronavirus disease 2019 -- 7. Metabolomics approach in differentiating RAS responses in ARDS (Acute respiratory distress syndrome) and SAR-CoV-2 -- 8. A Comprehensive review of the impact of the renin angiotensin system in the liver, lung, infectious diseases and cancers -- 9. Application of biosensors for monitoring changes in renin angiotensin system (RAS) in cancers and lung diseases -- 10. Bioinformatics study on renin angiotensin in lung, and liver cancer using plant-based extracts -- 11. Role of renin-angiotensin system in the pathogenesis and progression of non-alcoholic fatty liver -- 12. The classical and nonclassical renin-angiotensin-aldosterone system in liver cirrhosis -- 13. Renin-angiotensin-aldosterone system role in organ fibrosis -- 14. Role of renin angiotensin-aldosterone system in kidney homeostasis -- 15. Renin-angiotensin system in chronic kidney disease: Implications in stroke outcome -- 16. The renin-angiotensin system and cancer -- 17. Renin-angiotensin system and cancer: From laboratory to clinics -- 18. Role of renin-angiotensin system in cancer cachexia -- 19. Renin angiotensin system activity in different cancers: Mechanistic insight and preclinical studies -- 20. The new dimension of the renin-angiotensin system in the hallmarks of cancer -- 21. Renin-angiotensin system in hematological malignancies -- 22. Renin angiotensin system (RAS): The common thread between cancer and heart failure -- 23. Renin-angiotensin system: a potential therapeutic target for colorectal cancer -- 24. Anticancer role of natural phenolic acids by targeting angiotensin-converting enzyme (ACE) -- 25. Angiotensin-(1-7): A Prospective Cancer Therapeutic.

Description / Table of Contents: Global health and Viral diseases past, present and Future -- Drug resistance and statistics and patent status -- cellular understanding viral diseases -- Viral: current treatment options -- Mucosal drug delivery strategies for antiviral intervention -- Micro, nano emulsions in viral -- Novel formulation approaches to treat Ebola- virus -- Ebola- drug delivery -- Polymers for Bio sensing Applications in antiviral therapy and diagnosis -- Nanotechnology: A Stepping Stone towards Viral Hepatitis Treatment and Prevention in Children -- Recent Developments in the Treatment of Influenza -- Covid 19: from molecular pathogenesis to potential repurposed treatments -- Nano drug delivery systems for Covid-19-drug delivery -- Exploring the link between malaria and Covid 19 -- Characterization of biofunctionalized nanoparticles in ID -- Covid- azithromycin-ritonavir -- Strategies to combat Covid-19 drug delivery -- Phytomolecules and NDDS Covid-19.

Description / Table of Contents: Pharmacokinetics -- Chapter 1: Current status in PBPK modeling -- Chapter 2: Physiologically based biopharmaceutics modeling (PBBM) Application on Food Effect Assessment -- Chapter 3: Physiologically based finite time pharmacokinetic (PBFTPK) models: Inception and development -- Chapter 4: Physiologically based finite time pharmacokinetic (PBFTPK) models: Applications -- Pharmacodynamics -- Chapter 5: Pharmacokinetic – Pharmacodynamic Modelling and Simulation in Clinical Practice and Studies -- Chapter 6: On the Verge of Impossibility: Accounting for Variability Arising from Permutations of Comorbidities that Affect the Fate of Drugs in the Human Body -- Chapter 7: Impact of Clinical Pharmacology on the Modernization of Drug Development and Regulation.

Description / Table of Contents: Chapter 1: Current Status of Technology Transfer -- Chapter 2: Quality by Design (QbD) Process Design -- Chapter 3: Quality Risk Management (QRM) -- Chapter 4: Technology Transfer Process -- Chapter 5: Scaling-Up of Solid Orals: Granulation, Drying, Size Reduction, Blending, Compression, and Coating Technologies -- Chapter 6: Qualification, Continued Process Verification, and Lifecycle Management -- Chapter 7: Continuous Improvement Case Study: Transforming Legacy Products.

Description / Table of Contents: Part I: Oral Pharmacokinetics -- Chapter 1. From Bateman (1908) To Dost (1953) -- Chapter 2. The Unphysical Hypothesis Of Infinite Absorption Time -- Chapter 3. The Finite Absorption Time (Fat) Concept -- Chapter 4. The Rise Of Physiologically Based Finite Time Pharmacokinetic (Pbftpk) Models -- Part II: Bioavailability-Bioequivalence -- Chapter 5. History Of The Bioavailability-Bioequivalence Concepts -- Chapter 6. Therapeutic Equivalence Based On Bioequivalence Studies -- Chapter 7. Bioavailability Under The Prism Of Finite Absorption Time -- Chapter 8. Bioequivalence Under The Prism Of Finite Absorption Time.

Description / Table of Contents: Part 1: Patient-Centric Considerations.-Medicine Optimisation in Older -- Acceptability of drug formulations in older patients and effect on patient adherence -- Geriatric biopharmaceutics -- Excipient safety in older adults -- Part 2: Pharmaceutical Formulations Development for older Patients -- Oral and oromucosal formulation development and in vitro characterisation – patient-centric approaches for older adults -- Pulmonary drug delivery systems for older people -- Transdermal drug delivery systems for older patients -- Part 3 :Advanced Drug Delivery Systems for Older Patients -- Advanced oral drug delivery systems for older patients -- The ageing microbiome, pharmaceutical considerations and therapeutic opportunities -- Application of 3D printing in geriatric medicines, -- Application of electrospraying and advanced fabrication methods in geriatric medicines -- Vaccine development for older patients.

Description / Table of Contents: Part I: Manufacturing of Recombinant Therapeutic Proteins -- Chapter 1. Single-Use Systems in Biopharmaceutical Manufacture: State of the Art and Recent Trends (Jossen et al.) -- Chapter 2. Recent Developments in Bioprocess Monitoring Systems (Rahmatnejad et al.) -- Chapter 3. Advances in Characterization of Industrial Bioreactors for Cell Culture Process (Fitschen et al.) -- Chapter 4. Continuous Bioprocessing for Upstream Process - Perfusion Process (Chotteau et al.) -- Chapter 5. Continuous Bioprocessing for Downstream (Gerstweiler) -- Chapter 6. Towards Digital Twin for Biopharmaceutical Processes: Concept and Progress (Ding et al.) -- Chapter 7. Integrated Process and Supply Chain Design and Optimization (Triantafyllou et al.) -- Chapter 8. Production of Complex Proteins in Plants – From Farming to Manufacturing (Nausch et al.) -- Chapter 9. Manufacturing of Recombinant Proteins Using Quality by Design (QbD) Methodology: Current Trend and Challenges (Shin and Landauer) -- Chapter 10. Biopharma 4.0 for Biologics Manufacturing Under Pandemic Constraints (Schmidt et al.) -- Chapter 11. Biopharma 4.0: Digital Technologies Driving Smart Manufacturing (Nargund et al.) -- Part II: Manufacturing Aspects of Cell and Gene Therapy -- Chapter 12. Essential Aspects of Mesenchymal Stem Cell Manufacturing (Fleischhammer et al.) -- Chapter 13. Towards a Continuous Production of Human Mesenchymal Stromal Cells in a Chemically Defined Medium: Opportunities and Challenges for a Robust and Scalable Expansion Process (Tasto and Salzig) -- Chapter 14. Biomanufacturing Aspects of Gene Therapy (Warnock) -- Chapter 15. Manufacturing and Quality of Advanced Therapeutics: Cellular Therapies, CAR-T and Gene Therapies (van den Bos et al.).

Description / Table of Contents: Chapter 1: Introduction -- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience -- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines -- Chapter 3: Relevance for mRNA vaccine safety -- Chapter 4: From Challenges to Opportunities and Open Questions -- Chapter 5: The challenge of evaluating vaccine safety and effectiveness -- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development -- Chapter 7: Scales, pseudoscales, the human factor, and a way forward -- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta -- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection -- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs -- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen -- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion -- Part III: The Omicron variants -- Chapter 12: Omicron -- Chapter 13: Conclusion.

Description / Table of Contents: An Overview of the Anatomy and Physiology of the Nasal Passage from a Drug Delivery Point of View -- Pharmacological and Clinical Problems with a Special Focus on Nasal Drug Delivery -- Nasal as an Absorption Site: Opportunities and Challenges -- Factors Affecting the Design of Nasal Drug Delivery Systems -- Challenges in Targeting to the Nasal Passage -- Potential Targeting Sites to Brain Through the Nasal Passage -- Drug Absorption to Systemic Circulation after Nasal Drug Delivery -- Delivery of Vaccine through Nasal Drug Delivery System -- An Overview on Nano Carriers for Nasal Delivery -- Biomedical Applications of Nano Carriers in Nasal delivery -- Novel muco-adhesive polymers for nasal drug delivery -- Novel approaches in Nasal in situ gel drug delivery -- Nasal delivery of high molecular weight drugs recent trends and clinical evidence -- Nisosomes based drug delivery in targeting the brain tumors via nasal delivery -- Nano suspension- A Novel Drug Delivery System via Nose to Brain drug delivery -- Different Strategies for nose-to-brain delivery of protein and peptide molecules -- Regulatory requirements related to Nasal drug delivery -- Is there a global market and opportunities for nasal drug delivery. .

Description / Table of Contents: 3D and 4D printing in digital healthcare -- 3D Printing for Novel Dosage Form Design -- 3D Printing and regulatory considerations -- Printability of Pharmaceutical Polymers: Issues & Solutions -- Quality by Design (QbD) approach for individualized products based on additive manufacturing,- Material Properties and Selections for Additive Manufacturing (AM) -- Preformulation of 3D printable pharmaceutical dosage forms -- Vat photopolymerization Methods for Drug Delivery Applications -- Extrusion-based 3D printing methods for oral solid dosage forms -- Binder Jetting 3D Printing in Pharmaceutical Manufacturing -- Powder bed fusion 3D printing in drug delivery -- Bioprinting in Personalised Medications -- Shape memory materials and 4D printing in pharmaceutics -- Characterisation methods of final printed products.

Description / Table of Contents: Section-I: Introduction to nanomaterials for drug delivery -- Introduction to Nanomaterials for drug delivery -- Section-II: Nanomaterials-based drug delivery systems for Therapeutic applications -- Polymer-based nanomaterials -- Lipid-based nanomaterials -- Vesicular nanomaterials -- Hybrid nanomaterials -- Section-III: Nanomaterials-based drug delivery systems for Theranostic applications -- Magnetic nanoparticles -- Quantum dots -- Upconversion nanoparticles -- Gold nanoparticles -- Carbon-based nanoparticles -- Graphene-based nanoparticles -- Section-IV: Nanomaterials toxicity & clinical translation -- Nanotoxicology: an overview -- Patenting nanomaterials: Regulatory aspects -- Clinical perspectives: Translating nanomaterials from laboratory to clinic.

Description / Table of Contents: Part 1: Quality by Design (QbD) -- Chapter 1. Pharmaceutical Quality by Design (QbD) overview and major elements -- Chapter 2. Fundamentals of design of experiments and optimization: designs for factor screening and data analysis in pre-response surface methodology -- Chapter 3. Fundamentals of design of experiments and optimization: experimental designs in response surface methodology -- Chapter 4. Fundamentals of design of experiments and optimization: data modeling in response surface methodology -- Chapter 5. Quality by Design in pharmaceutical product and process development -- Chapter 6. A Quality by Design update on nano-drug delivery systems -- Chapter 7. Control strategies of solid dosage forms by PAT tools -- Part 2: Analytical Quality by Design (AQbD) -- Chapter 8. Analytical Quality by Design Fundamentals, Compendial and Regulatory Perspectives -- Chapter 9. Analytical Target Profile (ATP) and Method Operable Design Region (MODR) -- Chapter 10: Quality by Design applications to development of analytical methods for quality control of pharmaceuticals -- Chapter 11. Design of Experiments Applied to the Extraction of Active Compounds. .

Description / Table of Contents: Viral RNA as a Branched Polymer -- RNA Multiscale Simulations as an Interplay of Electrostatic, Mechanical Properties, and Structures Inside Viruses -- Establishing the Length Limit of RNA Packaged In Vitro by Spherical Virus-Like Particles -- The Multiple Regulatory Roles of Single-stranded RNA Viral Genomes in Virion Formation and Infection -- Creating Artificial Viruses using Self-assembled Proteins and Polypeptides -- Construction of Higher-order VLP-based Materials and Their Effect on Diffusion and Partitioning -- Assembly of Coronaviruses and CoV-like-particles -- Norovirus – A Viral Capsid in Perpetual Flux -- Structural Alterations in Non-enveloped Viruses During Disassembly -- Physical Virology with Atomic Force and Fluorescence Microscopies: Stability, Disassembly and Genome Release -- Virus Mechanics: A Structure-Based Biological Perspective -- Cryo-electron Microscopy and Cryo-electron Tomography of Viruses -- Bacteriophage Lambda as a Nano Theranostic Platform -- Therapeutic Interfering Particles (tips): Escape-Resistant Antiviral Against SARS-CoV-2.

Description / Table of Contents: Programmed Necrosis in Host Defense -- ZBP1/DAI-dependent Cell Death Pathways in Influenza A Virus Immunity and Pathogenesis -- Pyroptosis in Antiviral Immunity -- Manipulation of Host Cell Death Pathways by Herpes Simplex Virus -- Subversion of Programed Cell Death by Poxviruses -- Cell Killing by Reovirus: Mechanisms and Consequences -- Outcomes of RIP kinase signaling during neuroinvasive viral infection.

Description / Table of Contents: 1. Why study Zika? -- 2. Pandemic events are communication events -- 3. Zika re-emerges. -- 4. Zika ebbs -- 5. Convergence -- 6. Transmission -- 7. Effects on children, Part 1 -- 8. Effects on children, Part 2 -- 9. Effects on adults -- 10. Vectors and reservoirs management.

Description / Table of Contents: Bioanalytical Support in Drug Discovery and Development,- Monoclonal Antibodies -- Antibody Drug Conjugates (ADCS) -- Bispecifics and Fusion Proteins -- Emerging Modalities-Part A- (Gene Therapy and Cell Therapy) -- Emerging Modalities Part B (Peptides, Oligonucleotide Based Therapy, Vaccines. .

Description / Table of Contents: Chapter. 1. Molecular Farming in Plants: Introduction and Applications -- Chapter. 2. Tools and Techniques Used in Plant Molecular Farming -- Chapter. 3. Production of plant natural products in heterologous microbial species -- Chapter. 4. Sustainable Manufacturing of Vaccines, Antibodies, and other Pharmaceuticals -- Chapter. 5. Limitations, Biosafety, ethics, regulatory issues in molecular farming in plants -- Chapter. 6. Conclusion and Perspectives.

Description / Table of Contents: Chapter 1. Bacteriophages, a Brief Introduction -- Chapter 2. A Closer Overview of Phage Infections -- Chapter 3.Evolutionary Biology Basics -- Chapter 4. Brief Introduction to Phage Ecology -- Chapter 5.Bacterial Mutation Associated with Phages: Insertions -- Chapter 6. Bacterial Mutation Associated with Phages: Deletions -- Chapter 7. Genetic Drift and Phages -- Chapter 8. Phages and Asexual Bacterial Populations -- Chapter 9.Phage Impact on Non-Random Mating Among Bacteria -- Chapter 10. Genetic Migration and Phages -- Chapter 11. Bacterial Reproductive Isolation and Its Violation by Phages -- Chapter 12. Phage-Provided Environmental DNA and Superspreading -- Chapter 13. Transduction of Large Amounts of DNA -- Chapter 14. Phage Morons -- Chapter 15. Why Lysogenic Conversion? -- Chapter 16. Prophages Preventing Phage Superinfection -- Chapter 17. Domestication of Phage Genes -- Chapter 18.Resistance to Phages, Part I: Overview -- Chapter 19. Resistance to Phages, Part II: Bacteria Live! -- Chapter 20.Resistance to Phages, Part III: Bacteria Die..-Chapter 21. Bacterial Mutation to Phage Resistance -- Chapter 22. Pleiotropic Costs of Phage Resistance -- Chapter 23. Concepts of Natural Selection in Light of Phage Exposure -- Chapter 24. Frequency-Dependent Selection in Light of Phage Exposure -- Chapter 25. A Primer on Phage-Bacterium Antagonistic Coevolution.

Description / Table of Contents: Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs.

Description / Table of Contents: PART I. Polypharmacology as a New Branch of Pharmacology: Concept and Principles -- Basics of Polypharmacology -- Polypharmacology in Clinical Applications: Multitarget Multidrug-combination (MTMD-C) -- Polypharmacology in Clinical Applications: Multitarget Multidrug-single-formulation (MTMD-SF) -- Polypharmacology in Clinical Applications: Multitarget Single-drug (MTSD) -- Polypharmacology in Drug Discovery: Designed Epigenetic MTSD and Small-molecule MTSD -- Anti-cancer Polypharmacology -- Cardiovascular Polypharmacology -- Neuronal Polypharmacology -- Pulmonary Polypharmacology -- Polypharmacology of Metabolic Disease -- Polypharmacology of Infectious Disease -- Polypharmacology of Inflammation -- Anti-psychotics Polypharmacology -- Anti-aging Polypharmacology -- Polypharmacology in Drug Repurposing -- Polypharmacology and Unintended Drug Promiscuity -- Polypharmacology Pharmacokinetics -- The Future of Polypharmacology -- PART II. Polypharmacology in New Drug Development: Strategies and Protocols -- Designed MTSD Discovery Process -- Designed MTSD Discovery Strategies -- Designed MTSD Discovery Technologies -- Designed MTSD Discovery Databases -- Designed MTSD Target Deconvolution.-Designed MTSD Target Validation -- Designed MTSD Lead Identification and Optimization -- Designed MTSD Discovery Protocols -- Natural Products in MTSD Discovery -- Polypharmacology Procedures for Drug Repurposing -- Polypharmacology Procedures for Drug Promiscuity Discovery.

Description / Table of Contents: Part I Anatomy, Physiology and Pharmacology of Macrophages -- Introduction to Anatomy and Physiology of Macrophages from Drug Delivery Perspective -- Introduction to Pharmacology of Macrophages from Drug Delivery Perspective -- Mechanisms and Ways of Macrophage Delivery -- Macrophage Associated Disorders: Pathophysiology, Treatment Challenges and Possible Solutions -- Understanding Macrophage Associated Diseases and Applications of Nano Drug Delivery Systems -- Part II Polymeric Nanoparticles for Macrophage Targeting -- Targeting of Macrophages: Basic and therapeutic Role of Polymeric Nanoparticles -- Polymeric Nanoparticles Based Drug and Gene Delivery to Macrophages -- Surface Modification of Nanoparticles for Macrophage Targeting -- Part III Lipid Nanoparticles for Macrophage Targeting -- Liposomes as Delivery System for Macrophage Targeting -- Solid Lipid Nanoparticles Based Drug and Gene Delivery to Macrophages -- In vivo Fate of Colloidal Carriers Undergoing Macrophage Targeting -- Nanoparticle-based Theranostics for Macrophage-associated Diseases -- Part IV Targeting Macrophages for Treatment of Various Diseases -- Tumor Associated Macrophages as Therapeutic Target for Drug/immune Therapy of Cancer -- Macrophage Targeting for Therapy of Autoimmune Diseases -- Macrophage Targeting for Therapy of Cardiovascular Diseases (CVD) -- Macrophage targeting for therapy of intracellular infections -- Targeting Drugs and Nucleic Acids to Macrophages for Therapy of Inflammatory Diseases -- Macrophage Targeted Chemotherapy for Tuberculosis and other Respiratory Disease. -- Part V Specific Formulations and Clinical Trials on Macrophage Targeted Delivery -- Nano- and Microparticles Based Dry Powder Inhalers for Pulmonary Macrophage Drug Delivery -- Recent Trends in Clinical Studies on Macrophage Targeted Delivery -- Future Directions and Challenges in Macrophage Targeting. .

Description / Table of Contents: Therapeutic and toxic concentration of drugs in biological matrices -- Analytical techniques for therapeutic drug monitoring and clinical toxicology -- Plasma therapeutic drug monitoring and clinical toxicology -- Dried blood spots in therapeutic drug monitoring and toxicology -- The role of artificial intelligence in therapeutic drug monitoring and clinical toxicity -- Therapeutic drug monitoring and optimal pharmacotherapy with medicines of narrow therapeutic index -- Therapeutic drug monitoring (TDM) and toxicological studies in alternative biological matrices -- Analyzing data from therapeutic drug monitoring, pharmacokinetics, and clinical toxicology studies -- Reducing toxicity in critically ill patients by using therapeutic drug monitoring -- Quality assurance of samples for therapeutic drug monitoring and clinical toxicology -- Therapeutic drug monitoring and toxicology of anticancer drugs -- Therapeutic drug monitoring and toxicology of immunosuppressant -- Therapeutic drug monitoring and toxicology: relevance of measuring metabolites -- Recent advances in nanosensors for Therapeutic Drug Monitoring (TDM) -- Organ toxicity by immunosuppressive drugs in solid organ transplantation -- Artificial intelligence-based techniques to assess drug toxicity in drug induced liver injury (DILI) disease -- Drug dose and therapy individualization -- Models for drug individualization: patient to population level -- Toxicity evaluation of nanomedicine -- Biochemical indices of drug toxicity -- Therapeutic drug monitoring and clinical toxicology: challenges and future directions.

Description / Table of Contents: Chapter 1. What Should I Know About Drugs? -- Chapter 2. Painkillers (analgesics) -- Chapter 3. Drugs for Gastrointestinal Disorders -- Chapter 4. Drugs for Respiratory Diseases -- Chapter 5. Drugs for Cardiovascular Diseases -- Chapter 6. Drugs for Metabolic Disorders -- Chapter 7. Drugs for Her and Him -- Chapter 8. Drugs for Neurological Disorders -- Chapter 9. Drugs for Mental Disorders -- Chapter 10. Drugs for Eye Diseases -- Chapter 11. Drugs for Cancer and Autoimmune and Infectious Diseases.

Description / Table of Contents: Goals for DMPK during drug optimizations -- Drug Properties -- DMPK in lead optimization -- Candidate tranlational characterization -- Q&A of DMPK issues and tools for drug discovery -- ADME assays -- Regulatory documents for IND to Support FIH -- Appendix: Chemical nomenclature.

Description / Table of Contents: Compliance with the Surgery Safety Checklist: An Update on the Status -- Surgical Safety Checklist: Polychromatic or Achromatic Design -- Surgical Strategy and Clinical Outcome in Patients with Bronchial Carcinoids -- Frozen Section or Intraoperative Cytology: Are We Ready for a Paradigm Shift in Thoracic Surgery? -- Clinical Outcome in Patients with Nosocomial COVID-19 Infection After Thoracic Surgery -- Cytological Diagnostic Procedures in Malignant Mesothelioma -- Combination of Biochemical and Cytological Findings for Better Diagnosis in Pleural Effusions -- Cytokines in Renal Cell Carcinoma: A Step Towards Earlier Detection and Targeted Therapy -- Primary Hyperparathyroidism Secondary to Ectopic Parathyroid Adenoma: A Case Report -- Perception of Well-Being and Quality of Life in Obese Patients After Bariatric Surgery -- Do Multiple Brain Lesions Always Connote Worse Outcomes? Appraisal Evidence from a Tertiary Care Center in Koshi/Purbanchal Province of Nepal -- Radioimaging and Demographic Profiles of Patients with Spontaneous Intracerebral Hemorrhage: A Need for the Pragmatic Referral System -- Anticytokine Treatment of Rheumatoid Arthritis: An Observational Report.

Description / Table of Contents: Preface -- Molecular Virology of Chikungunya Virus -- Understanding molecular pathogenesis with chikungunya virus research tools -- Chronic Chikungunya Virus Disease -- Chikungunya Virus Vaccines: Platforms, Progress, and Challenges -- Small Molecule Inhibitors Targeting Chikungunya Virus.

Description / Table of Contents: Chapter 1: Achillea biebersteinii Afan -- Chapter 2: Aesculus hippocastanum L. -- Chapter 3: Berberis crataegina DC. -- Chapter 4: Calendula officinalis L. -- Chapter 5: Camellia sinensis (L.) Kuntze -- Chapter 6: Capsella bursa-pastoris (L.) Medik. -- Chapter 7: Capsicum annuum L. -- Chapter 8: Cedrus libani A.Rich. -- Chapter 9: Chelidonium majus L. -- Chapter 10: Cichorium intybus L. -- Chapter 11: Cistus laurifolius L. -- Chapter 12: Coriandrum sativum L. -- Chapter 13: Cornus mas L. -- Chapter 14: Curcuma longa L..-Chapter 15: Cydonia oblonga Mill. -- Chapter 16: Cynara scolymus L. -- Chapter 17: Equisetum arvense L. -- Chapter 18: Foeniculum vulgare Mill. -- Chapter 19: Fraxiınus ornus L. -- Chapter 20: Fumaria officinalis L. -- Chapter 21: Helichrysum plicatum DC. -- Chapter 22: Hyoscyamus niger L. -- Chapter 23: Juglans regia L. -- Chapter 24: Laurus nobilis L. -- Chapter 25: Liquidambar orientalis Miller -- Chapter 26: Matricaria chamomilla L. -- Chapter 27: Melissa officinalis L. -- Chapter 28: Momordica charantia L. -- Chapter 29: Nigella sativa L. -- Chapter 30: Olea europaea L. -- Chapter 31: Papaver somniferum L. -- Chapter 32: Rheum ribes L. -- Chapter 33: Rosa canina L. -- Chapter 34: Rosmarinus officinalis L. -- Chapter 35: Silybum marianum L. Gaertn. -- Chapter 36: Urtica dioica L -- Chapter 37: Valeriana officinalis L. -- Chapter 38: Viburnum opulus L.

Description / Table of Contents: Part 1-Modelling of PK/PD for NPDDS -- Introduction to Nanoparticulate Drug Delivery Systems -- Nanoparticle Properties Affecting Pharmacokinetics of NPDDS -- Models Used for Biopharmaceutical Evaluation of NPDDS -- Models Used in the Pharmacokinetic Evaluation of NPDDS -- Models Used in the Pharmacodynamic Evaluation of NPDDS -- Preclinical Animal Models For Experimental Design of Pharmacokinetic Studies of NPDDS -- Pharmacokinetic Modelling Program (PKMP) -- Part 2-PK/PD for Specific Nanocarriers -- Pharmacokinetic and Pharmacodynamics of Liposomal Nanoparticles -- Pharmacokinetics of Polymer Matrix Drugs (NPDDS) -- Pharmacokinetics of Long-Circulating NPDDS -- Metallic Gold Nanoparticles in vivo Pharmacokinetics and X-ray Contrast imaging Studies -- Muco-adhesive NPDDS In Vitro and Pharmacokinetics Studies -- Pharmacokinetic and Tissue Distribution Study of Solid Lipid Nanoparticles -- Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles -- PKPD of PLGA-PEG-PLGA Triblock CoPolymeric Micelles -- Part 3-PKPD in Diseased Conditions for NPDDS -- Bridging Bio-Nanoscience and Cancer Nanomedicine -- Clearance Pathways and Tumor Targeting of Imaging Nanoparticles for Diagnostics -- PLGA Nanoparticles for Oral Delivery-Nephrotoxicity and Pharmacokinetic Studies -- Pharmacokinetics of Nanoparticle Systems for Pulmonary Delivery -- In vivo Biodistribution and Pharmacokinetic Studies of NPDDS for Brain Targeting -- Enhanced Bioavailability and Intestinal Uptake Nanoparticles After Oral Delivery -- Nanoparticle Pharmacokinetic Profiling In Vivo Using Magnetic Resonance Imaging.

Description / Table of Contents: Drying -- Mixing -- Comminution -- Filtration -- Pharmaceutical Packaging -- Oral Emulsion -- Oral Suspensions -- Tablets and Capsules -- Oral Inhalers -- Topically Applied Products -- Sterile Products -- Industrial Hazards -- Modified Release Drug Delivery Systems -- Novel Drug Delivery System -- Polymer for Biomedical Applications -- Biotechnology Based Drugs.

Description / Table of Contents: Basic Concepts of Design of Peptide based Therapeutics -- Computational Methods in Peptide Based Drug Design -- Synthesis, Purification, and Characterization of Linear and Cyclic Peptides -- Large Scale Synthesis of Peptides, Manufacturing Peptide Therapeutics -- Stability of Peptides -- Peptide Delivery Systems -- Liposomes and Nanoparticle Formulations for Peptide Delivery -- Delivery of Peptides Across the Blood-brain Barrier (BBB) -- Peptide Therapeutics Regulatory Considerations.

Description / Table of Contents: Part I-Physiology and Basic Principles of Drug Handling for the CNS -- Anatomy and Physiology of the Blood Brain Barriers -- Drug Delivery to the Brain: Integrating Neuroscience, Physiology, and Brain Barriers Science -- Brain Delivery of Therapeutics via Transcytosis: Types and Mechanisms of Vesicle-Mediated Transport Across the BBB -- Brain- Arachnoid Barrier as an Important Clearance Pathway from CSF -- BBB Pharmacoproteomics: Quantitative Targeted Absolute Proteomics (QTAP): Species Differences -- Drug Metabolism at the BBB and the BCFSB -- PART II-PK Concepts and Methods for Studying CNS Drug Delivery -- Pharmacokinetics Concepts in Brain Drug Delivery -- In Vitro Models of CNS Barriers -- Human In Vitro BBB Models Derived from Pluripotent Stem Cells -- In situ and In vivo Animal Models -- Principles of PET and Its Role in Understanding Drug Delivery to the Brain -- Prediction of CNS PK and PD Using Translational Research Approaches -- Part III-Industrial Approaches for Investigation of Potential CNS Drugs -- Drug Discovery Methods for Studying Brain Drug Delivery and Distribution -- Prediction of Drug Exposure in the Brain From the Chemical Structure -- Integrated Approach to Optimizing CNS Penetration in Drug Discovery -- Part IV: Strategies for Improved CNS Drug Delivery -- Intranasal Drug Delivery to the Brain -- Blood to Brain Drug Delivery Using Nanocarriers -- Enhancing CNS Exposure Through Brain Endothelial Cell RMT-Exploiting the Transferrin Receptor at the BBB -- Therapeutic Osmotic Modification of the BBB in the Treatment of CNS Pathologies -- Biophysical Perspectives on BBB Permeability Enhancement by Ultrasound and Microbubbles for Targeted Drug Delivery in the Clinical Setting -- Optimization of Blood Brain Barrier Opening With Focused Ultrasound-The Animal Perspective -- CNS Gene Therapy Using Adeno-Associated Virus (AAV) Vectors -- Part V-CNS Drug Delivery in Disease Conditions -- Disease Influence on BBB Transport in Neurodegeneration and Neuroinflammation -- Enhancing Drug Delivery in the Setting of Stroke and Brain Injury -- Drug Delivery to tumor Metastases in the Brain-(Including PK PD Free Fraction Active Conc.) -- Drug Delivery to Primary Tumors in the Brain-(Including PK PD Free Fraction Active Conc.) -- Appendix:CNS Anatomy, Function, Vasculature and Fluid Exchange: Primer for Drug Delivery Scientists.

Description / Table of Contents: 1. Therapeutic potential of microRNAs and their nanoparticle-based delivery in the treatment of liver fibrosis -- 2. MicroRNA as a versatile regulator of Wnt signaling pathway in colorectal cancer -- 3. Small Activating RNA Therapy for Angiogenesis -- 4. Muscular dystrophy therapy using viral vector-based CRISPR/Cas -- 5. CRISPR-Cas based gene therapy to target viral infections -- 6. CRISPR targeting the integrated HTLV-1 virus -- 7. Retroviral vectors for gene therapy of monogenic diseases -- 8. DNA Origami Nanodevices for Therapeutic Delivery Applications.

Description / Table of Contents: 1 The Question of Life -- 2 Families, Forms, and Functions -- 3 Ancient or New – On the Origin of Viruses -- 4 Of Predators and Prey -- 5 Immunity, Immunity, Immunity -- 6 Viruses That Shaped Our World -- 7 SV40 - An Obscure Monkey Virus and the Golden Age of Molecular Biology -- 8 Viral Cancer -- 9 The Viruses Within - How Human Are We? -- 10 Vaccines and the Conquest of Viruses -- 11 New and Emerging Viruses -- 12 Beyond Antibiotics – Are Phages our Allies? -- 13 Viruses in Gene Therapy and Cancer Therapeutics.

Description / Table of Contents: Drug discovery paradigms: target-based drug discovery -- Drug discovery paradigms: phenotypic-based drug discovery -- Target Identification Approaches in Drug Discovery -- Introduction to target validation -- Structure-based binding pocket detection and druggability assessment -- Network-Based Target Identification -- The Current State of Precision Medicine and Targeted-Cancer Therapies – Where are We? -- Metabolic Control Analysis for drug target selection against human diseases -- Progress on open chemoinformatic tools for drug discovery.

Description / Table of Contents: Section I: General, Identity and Taxonomy -- The genus Phoma: What we know and what we need to know? -- Taxonomical evaluation of Phoma- history of classification, current status and future directions -- Section II: Diversity, Diseases and Host Range -- Phoma on medicinal and aromatic plants -- Diseases of fruits, tubers, and seeds caused by Phoma sensu lato species complex -- Overview of Phoma-like fungi on important legumes (Papilionaceous plants) -- Diseases of vegetables caused by Phoma spp -- Phoma diseases: identification, epidemiology and strategies for management -- Major plant diseases caused by Phoma sensu lato species and their integrated management strategies -- Phoma as an infectious pathogen in medical practice -- Section III: Secondary metabolites and Bioactivities -- Fruitful decade of Phoma secondary metabolites from 2011 to 2020: Chemistry, chemical diversity and biological activities -- Bioactive secondary metabolites from endophytic Phoma spp -- The genus Phoma: a review of its potential bioactivities, implications and prospects -- Bioherbicidal activity of Phoma macrostoma -- New technologies for the formulation of secondary metabolites produced by Phoma sp. for biological control of weeds -- Biological management of plant diseases by non-pathogenic Phoma spp -- Plant growth promoting Phoma spp -- Section IV:Nanotechnology and Fossil records of Phoma -- Potential role of Phoma spp. for mycogenic synthesis of Silver nanoparticles -- In situ occurrence of Phomites Fritel in the phyllosphere of ancient Siwalik forests of eastern Himalaya during the Mio-Pleistocene.

Description / Table of Contents: Ch 1: Electron Spin Resonance- An Introdcution -- Ch 2: ESR – Applications in Healthcare and Pharmaceutical Science -- Ch 3: ESR Applications in Paleontology and Geochronology -- Ch 4: ESR Applications in Food Science.

Description / Table of Contents: I. Neuropathogenesis and Biomarkers -- New Potential Axes of HIV Neuropathogenesis with Relevance to Biomarkers and Treatment -- Neurocognitive Impairment and Associated Genetic Aspects in HIV Infection -- Inflammatory Mechanisms and Cascades Contributing to Neurocognitive Impairment in HIV/AIDS -- Neuroimaging Advances in Diagnosis and Differentiation of HIV, Comorbidities, and Aging in the cART Era -- II. Neurocognitive Impairments in Low-, Middle- and High-Income Countries – Incidence / Prevalence and Contexts -- Neurocognitive Complications of Pediatric HIV Infections -- Neurocognitive Complications of HIV Infection in Women: Insights from the WIHS Cohort -- Cultural Neuropsychology Considerations in the Diagnosis of HIV- Associated Neurocognitive Disorders -- Neurocognitive Complications of HIV Infection in Low-Income Countries -- Deep Phenotyping of HIV Neurocognitive Complications Among Individuals Residing in High-Income Countries -- Reliably Measuring Cognitive Change in the Era of Chronic HIV Infection and Chronic HIV-Associated Neurocognitive Disorders -- III. Comorbidities and Complications -- Geriatric Syndromes in People Living with HIV Associated with Ageing and Increasing Comorbidities: Implications for Neurocognitive Complications of HIV Infection -- Conceptualizing and Assessing Everyday Functioning in the Context of HIV-Associated Neurocognitive Disorders -- Neuropsychiatric Disorders, Emotional Disturbances, and Their Associations with HIV-Associated Neurocognitive Disorder -- Metabolic Syndrome and Cardiovascular Disease Impacts on the Pathophysiology and Phenotype of HIV-Associated Neurocognitive Disorders -- HIV-Associated Neurocognitive Disorder (HAND): Relative Risk Factors -- IV. Screening, Interventions and Clinical Management -- Screening for HIV-Associated Neurocognitive Disorders: Sensitivity and Specificity -- Behavioral and Physical Activity Interventions for HAND -- Targeting HIV-Related Neurocognitive Impairments with Cognitive Training Strategies: Insights from the Cognitive Aging Literature -- Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants.

Description / Table of Contents: Clinical features, diagnostic evaluation and management of COVID-19 patients -- Outbreak of COVID-19: A Detailed Overview and Its Consequences -- A paradigm gap in host-pathogen interaction studies: Lesson from the COVID-19 pandemic -- SARS/CoV-2: Behavioral Host Manipulation -- Management of COVID-19 in the Intensive Care Unit -- First wave of Covid-19 pandemic in Italy: data and evidence -- Risk factors for COVID-19: diabetes, hypertension and obesity -- Current challenges for the effective management of the COVID-19 pandemic -- COVID-19 Outbreak Challenges in Indian Migrant Pregnant and Lactating Mothers: Learnt Lesson Demands Phronesis and Hierarchical Strategies for Such Future Pandemics -- COVID-19 and Extracorporeal Membrane Oxygenation -- COVID-19's Clinical-Pathological Evidence in Relation to its Repercussion on the Central and Peripheral Nervous System -- Anatomopathological Aspects and Clinical Correlation of COVID-19: A Systematic Review -- SARS-CoV-2 liability: the hidden mystery behind its presentation in children.

Description / Table of Contents: Origin and structural biology of Novel Coronavirus (SARS-CoV-2) -- The Molecular Virology of Coronaviruses with Special Reference to SARS-CoV-2 -- Epidemiology, transmission and molecular immunopathology of SARS-CoV-2 -- Epidemiology and Etiopathogeny of Covid-19 -- Immunological and Hematological Response in COVID-19 -- Toll-like receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective -- Potential drug strategies to target Coronaviruses -- Possible therapeutic intervention strategies for COVID-19 by manipulating the cellular proteostasis network -- The potential impact of statins in the treatment of patients with COVID-19 infection -- Anticoronavirus activity of water-soluble pristine C60 fullerenes: in vitro and in silico screening -- Application of Nanoscale materials and nanotechnology against viral infection: A special focus on Coronaviruses -- Obesity: A Risk Factor for Covid-19 -- Cytokine Storm and Failed Resolution in COVID-19: Taking Cue from Multiple Sclerosis.

Description / Table of Contents: SARS-CoV-2 (COVID-19): Beginning to Understand a New Virus -- Neurological Complications of the COVID-19 Pandemic: What have we got so Far? -- Endothelial Dysfunction as a Primary Consequence of SARS-CoV-2 Infection -- A Review Study on the Neonatal Outcomes of Pregnant Women with COVID-19 -- Relationship between COVID-19 and Angiotensin-Converting Enzyme 2: A Scoping Review -- Experience in Nutrition Management of Diabetes-affected COVID-19 Patients -- Emerging Technologies for the Treatment of COVID-19 -- Obesity and risk of COVID-19 infection and severity: available evidence and mechanisms -- COVID-19 is an Endothelial Disease: Implications of Nitric Oxide -- Immune Response and Effectiveness of COVID-19 Therapies -- The Novel Coronavirus and Inflammation -- Does SARS-CoV-2 Threaten Male Fertility? -- COVID-19 and Vulnerable Populations in Sub-Saharan Africa: a Review -- Overview of the Haematological Effects of COVID-19 Infection -- The Novel Coronavirus and Haemostatic Abnormalities: Pathophysiology, Clinical Manifestations and Treatment Recommendations -- COVID-19 related laboratory analyte changes and the relationship between SARS-CoV-2 and HIV, TB and HbA1c in South Africa -- The Primary Outcomes, Epidemiological and Clinical Features of Coronavirus Disease-2019 (COVID-19) in Iran -- Acute Respiratory Distress Syndrome and COVID-19: A Scoping Review and Meta-Analysis -- Depression, Anxiety and Stress Among Patients with COVID-19: A Cross-sectional Study -- Survey of Immediate Psychological Distress Levels among Health Care Workers in the COVID-19 Epidemic: A Cross-sectional Study -- Coronavirus (COVID-19)-Associated Psychological Distress Among Medical Students in Iran -- A Survey of Psychological Distress among the Community in the COVID-19 Epidemic: A Cross-Sectional Study -- Gender Susceptibility to COVID-19 Mortality: Androgens as the Usual Suspects? -- Identification, Monitoring and Prediction of Disease Severity in Patients with COVID-19 Pneumonia Based on Chest Computed Tomography Scans: a Retrospective Study -- The Level of Procalcitonin in Severe COVID-19 Patients: A Systematic Review and Meta-analysis -- A Systematic Review of 571 Pregnancies Affected by COVID-19 -- The 2019 Novel Coronavirus Disease in Pregnancy: A Systematic Review -- Acute Kidney Injury and Covid-19: a Scoping Review and Meta-analysis -- Cardiac Injury in COVID-19: A Systematic Review -- A Systematic Review of the Assessment of the Presence of SARS-CoV-2 in Human Semen -- Index.

Description / Table of Contents: 1.Introduction to black cumin (Nigella sative): Chemistry, Technology, Functionality and Applications -- Section 1. Nigella sative seeds: Cultivation, Composition and Applications -- 2. Effect of cultivation, fertilization and irrigation practices on Nigella sative yield and quality -- 3. Morphological characters of Nigella sativa -- 4. Micro and macroscopic characterization of traded Nigella sativa seeds using applied systematics techniques -- 5. Composition of Nigella sativa seeds -- 6. Nigella sativa seed peptides (Thionins) -- 7. Black cumin polysaccharides -- 8. Thymoquinone: Chemistry and cunctionality -- 9. Novel Prospective of Nigella sativa Essential Oil Analysis, Culinary and Medicinal Uses -- 10. Rediscovering Nigella Seeds Bioactives Chemical Composition using Metabolomics Technologies -- 11. Health promoting activities of Nigella sativa seeds -- 12. Nigella sativa seed extract in green synthesis and nanocomposite -- 13. Food applications of Nigella sative seeds -- 14. Nutraceutical importance and applications of Nigella sativa seed flour -- 15. Nigella sativa seed cake: nutraceutical significance and applications in the food and cosmetic industry -- 16. Nigella sative seeds in cosmetic products -- 17. Nigella sativa supplementation in ruminant diets: production, health, and environmental perspectives -- 18. Nigella sativa seeds and its derivatives in poultry feed -- 19. Nigella sative Seeds and Its Derivatives in Fish Feed -- Section 2: Nigella sative fixed oil: Chemistry, Technology, Functionality and Applications -- 20. Composition and Functionality of Nigella sativa Fixed Oil -- 21. Effect of processing on the composition and quality of Nigella sativa fixed oil -- 22. Food applications of Nigella sativa Fixed Oil -- 23. Health-Promoting Activities of Nigella sativa Fixed Oil -- 24. Micro- and Nano-encapsulation of Nigella sativa Oil -- 25. Biodiesel Production Potential of Nigella sativa Oil -- Section 3: Nigella sative essential oil: Chemistry, Technology, Functionality and Applications -- 26. Composition and functionality of Nigella sativa essential oil -- 27. Effect of processing on the composition and quality of Nigella sativa essential oil -- 28. Food applications of Nigella sativa essential oil -- 29. Health-promoting activities of Nigella sativa essential oil -- Section 4: Nigella sative seed extracts: Chemistry, Technology, Functionality and Applications -- 30. Composition and Functionality of Nigella sativa Seed Extracts -- 31. Nigella sativa seed extracts in functional foods and nutraceutical applications -- 32. Health promoting activities of Nigella sativa seed extracts.

Description / Table of Contents: Chapter 1. Introduction on Coronavirus Disease (COVID-19) Pandemic: The Global Challenge (Nima Rezaei, Saboura Ashkevarian, Mahsa Keshavarz Fathi, Sara Hanaei, Zahra Kolahchi, Seyedeh-Sanam Ladi Seyedian, Elham Rayzan, Mojdeh Sarzaeim, Aida Vahed, Kawthar Mohamed, Sarah Momtazmanesh, Negar Moradian, Zahra Rahimi Pirkoohi, Noosha Sameeifar, Mahsa Yousefpour, Sepideh Sargoli, Saina Adiban, Aida Vahed, Niloufar Yazdanpanah, Heliya Ziaei, Amene Saghazadeh) -- Chapter 2. Coronaviruses: What Should We Know About the Characteristics of Viruses? (Wei Ji) -- Chapter 3. Ecology and Evolution of Betacoronaviruses (Eduardo Rodríguez-Román, Adrian J. Gibbs) -- Chapter 4. The Epidemiologic Aspects of COVID-19 Outbreak: Spreading Beyond Expectations (Sara Hanaei, Farnam Mohebi, Maziar Moradi-Lakeh, Parnian Jabbari, Surinder Kumar Mehta, Liudmyla S. Kryvenko, Livio Luongo, Loďc Dupré, Nima Rezaei) -- Chapter 5. The Incubation Period of COVID-19: Current Understanding and Modeling Technique (Char Leung) -- Chapter 6. Coronavirus: Pure Infectious Disease or Genetic Predisposition (Farzaneh Darbeheshti, Hassan Abolhassani, Mohammad Bashashati, Saeid Ghavami, Sepideh Shahkarami, Samaneh Zoghi, Sudhir Gupta, Jordan S. Orange, Hans D. Ochs, Nima Rezaei) -- Chapter 7. Genetic Polymorphisms in the Host and COVID-19 Infection (Joris R. Delanghe, Marc L. De Buyzere, Marijn M. Speeckaert) -- Chapter 8. How COVID-19 Has Globalized: Unknown Origin, Rapid Transmission, and the Immune System Nourishment (Amene Saghazadeh, Nima Rezaei) -- Chapter 9. Potential Anti-viral Immune Response Against COVID-19: Lessons Learned from SARS-CoV (Mahzad Akbarpour, Laleh Sharifi, Amir Reza Safdarian, Pooya Farhangnia, Mahdis Borjkhani, Nima Rezaei) -- Chapter 10. COVID-19 and Cell Stress (Abdo A Elfiky, Ibrahim M Ibrahim, Fatma G Amin, Alaa M Ismail, Wael M Elshemey) -- Chapter 11. Clinical Manifestations of COVID-19 (Mahsa Eskian, Nima Rezaei) -- Chapter 12. Pediatrics and COVID-19 (Tuna Toptan, Sandra Ciesek, Sebastian Hoehl) -- Chapter 13. Geriatrics and COVID-19 (Mona Mirbeyk, Amene Saghazadeh, Nima Rezaei) -- Chapter 14. Coronavirus Diseases in Pregnant Women, the Placenta, Fetus, and Neonate (David A. Schwartz, Amareen Dhaliwal) -- Chapter 15. COVID-19 in Patients with Hypertension (Thiago Quinaglia, Mahsima Shabani, Nima Rezaei) -- Chapter 16. COVID-19 and Cardiovascular Diseases (Babak Geraiely, Niloufar Samiei, Parham Sadeghipour, Azita Haj Hossein Talasaz, Seyedeh Hamideh Mortazavi, Roya Sattarzadeh Badkoubeh) -- Chapter 17. How Prevalent Is Cancer in Confirmed Cases with Coronaviruses and Severe Acute Respiratory Syndromes? (Maryam Fotouhi, Elham Samami, Sahar Mohseni, Amir Nasrollahizadeh, Mohammad Haddadi, Mona Mirbeyk, Amene Saghazadeh, Nima Rezaei) -- Chapter 18. COVID-19 in Patients with Cancer (Ali Nowroozi, Sepideh Razi, Kamal Kant Sahu, Fabio Grizzi, Jann Arends, Mahsa Keshavarz-Fathi, Nima Rezaei) -- Chapter 19. COVID-19 and Tropical Infection: Complexity and Concurrence (Pathum Sookaromdee, Viroj Wiwanitkit) -- Chapter 20. Neurologic Manifestations of COVID-19 (Farnaz Delavari, Farnaz Najmi Varzaneh, Nima Rezaei) -- Chapter 21. Autoimmune Processes Involved in Organ System Failure Following Infection with SARS-CoV-2 (Steven E. Kornguth, Robert J. Hawley) -- Chapter 22. Clinical and Laboratory Predictors of Severity, Criticality, and Mortality in COVID-19: A Multisystem Disease (Bahareh Gholami, Samira Gholami, Amir Hossein Loghman, Behzad Khodaei, Simin Seyedpour, Nasrin Seyedpour, Amene Saghazadeh, Nima Rezaei) -- Chapter 23. Diagnostic Tests for COVID-19 (Tung Phan, Kristin Nagaro) -- Chapter 24. The Role of Medical Imaging in COVID-19 (Houman Sotoudeh, Masoumeh Gity) -- Chapter 25. Therapeutic Development in COVID-19 (Chan Yang, Yuan Huang, Shuwen Liu) -- Chapter 26. Immune-based Therapy for COVID-19 (Abdolreza Esmaeilzadeh, Davood Jafari, Safa Tahmasebi, Reza Elahi, Elnaz Khosh) -- Chapter 27. Ventilatory Support in Patients with COVID-19 (Paolo Maria Leone, Matteo Siciliano, Jacopo Simonetti, Angelena Lopez, Tanzira Zaman, Francesco Varone, Luca Richeldi) -- Chapter 28. Nutrition and Immunity in COVID-19 (Marjan Moallemian Isfahani, Zahra Emam-Djomeh, Idupulapati M. Rao, Nima Rezaei) -- Chapter 29. Dietary Supplements for COVID-19 (Gerard E. Mullin, Berkeley Limektkai, Lin Wang, Patrick Hanaway, Loren Marks, Edward Giovannucci) -- Chapter 30. Photobiomodulation and Antiviral Photodynamic Therapy in COVID-19 Management (Reza Fekrazad, Sohrab Asefi, Maryam Pourhajibagher, Farshid Vahdatinia, Sepehr Fekrazad, Abbas Bahador, Heidi Abrahamse, Michael R Hamblin) -- Chapter 31. The COVID-19 Vaccine Landscape (Till Koch, Anahita Fathi, Marylyn M. Addo) -- Chapter 32. Prevention of COVID-19: Preventive Strategies for General Population, Health Care Settings, and Various Professions (Shirin Moossavi, Kelsey Fehr, Hassan Maleki, Simin Seyedpour, Mahdis Keshavarz-Fath, Farhad Tabasi, Mehrdad Heravi, Rayka Sharifian, Golnaz Shafiei, Negin Badihian, Roya Kelishadi, Shahrzad Nematollahi, Majid Almasi, Saskia Popescu, Mahsa Keshavarz-Fathi, Nima Rezaei) -- Chapter 33. Pharmacist Role and Pharmaceutical Care during the COVID-19 Pandemic (Pedro Amariles, Mónica Ledezma-Morales, Andrea Salazar-Ospina, Jaime Alejandro Hincapié-García) -- Chapter 34. Impact of COVID-19 on Dentistry (Arghavan Tonkaboni, Mohammad Hosein Amirzade-Iranaq, Heliya Ziaei, Amber Ather) -- Chapter 35. The Implications of COVID-19 to Ophthalmology (Tracy H.T. Lai, Emily W.H. Tang, Kenneth K.W. Li) -- Chapter 36. Challenges of Cellular therapy during COVID-19 Pandemic (Kamal Kant Sahu, Sikander Ailawadhi, Natalie Malvik, Jan Cerny) -- Chapter 37. COVID-19 Amid Rumours and Conspiracy Theories: The Interplay between Local and Global Worlds (Inayat Ali) -- Chapter 38. Exploration of the Epidemiological and Emotional Impact of Quarantine and Isolation during COVID‐19 Pandemic (Helia Mojtabavi, Nasirudin Javidi, Anne-Frédérique Naviaux, Pascal Janne, Maximilien Gourdin, Mahsa Mohammadpour, Amene Saghazadeh, Nima Rezaei) -- Chapter 39. The Main Sources and Potential Effects of COVID-19-related Prejudice and Discrimination (Piotr Rzymski, Hanna Mamzer, Michał Nowicki) -- Chapter 40. Potential mechanisms of COVID-19-related psychological problems and mental disorders (Chunfeng Xiao) -- Chapter 41. Mental Health in Health Professionals in the COVID-19 Pandemic (Antonia Bendau, Andreas Ströhle, Moritz Bruno Petzold) -- Chapter 42. Treatment of Patients with Mental Illness Amid a Global COVID-19 Pandemic (Ankit Jain, Kamal Kant Sahu, Paroma Mitra) -- Chapter 43. A Shift in Medical Education During the COVID-19 Pandemic (Farida Nentin1, Nagaraj Gabbur, Adi Katz) -- Chapter 44. Reopening Schools After a Novel Coronavirus Surge (Dan Li, Elizabeth Z. Lin, Marie A. Brault, Julie Paquette, Sten H. Vermund, Krystal J. Godri Pollitt) -- Chapter 45. COVID-19 and Its Impact on Tourism Industry (Dimitrios G. Lagos, Panoraia Poulaki, Penny Lambrou) -- Chapter 46. COVID-19 and Its Global Economic Impact (Zahra Kolahchi, Manlio De Domenico, Lucina Q. Uddin, Valentina Cauda, Igor Grossmann, Lucas Lacasa, Giulia Grancini, Morteza Mahmoudi, Nima Rezaei) -- Chapter 47. Retrieval and Investigation of Data on SARS-CoV-2 and COVID-19 Using Bioinformatics Approach (Muhamad Fahmi, Viol Dhea Kharisma, Arif Nur Muhammad Ansori, Masahiro Ito) -- Chapter 48. Answering the Challenge of COVID-19 Pandemic through Innovation and Ingenuity (Kathryn Clare Kelley, Jonathan Kamler, Manish Garg, Stanislaw P. Stawicki) -- Chapter 49. COVID-19 Pandemic: The Influence of Culture and Lessons for Collaborative Activities (Linda Simon Paulo, George M. Bwire, Xingchen Pan, Tianyue Gao, Amene Saghazadeh, Chungen Pan) -- Chapter 50. A Borderless Solution Is Needed for A Borderless Complexity, Like COVID-19, The Universal Invader (Kawthar Mohamed, Rangarirai Makuku, Eduardo Rodríguez-Román, Aram Pascal Abu Hejleh, Musa Joya, Mariya Ivanovska, Sara A. Makka, Md Shahidul Islam, Nesrine Radwan, Attig-Bahar Faten, Chunfeng Xiao, Leander Marquez, Nima Rezaei) -- Chapter 51. Socialization During The COVID-19 Pandemic: The Role of Social and Scientific Networks During Social Distancing (Sara Momtazmanesh, Noosha Samieefar, Lucina Q. Uddin, Timo Ulrichs, Roya Kelishadi, Vasili Roudenok, Elif Karakoc-Aydiner, Deepak B. Salunke, Jan L. Nouwen, Juan Carlos Aldave Becerra, Duarte Nuno Vieira, Ekaterini Goudouris, Mahnaz Jamee, Morteza Abdullatif Khafaie, Morteza Shamsizadeh, Mohammad Rasoul Golabchi, Alireza Samimiat, Donya Doostkamel, Alireza Afshar, Mohammad Amin Khazeei Tabari, Melika Lotfi, Reza Yari Boroujeni, Niloofar Rambod, Anzhela Stashchak, Alla Volokha, Dainius Pavalkis, André Pereira, Amir Hamzah Abdul Latiff, Rauf Baylarov, Bagher Amirheidari, Mojtaba Hedayati, Antonio Condino-Neto, Nima Rezaei) -- Chapter 52. Interdisciplinary Approaches to COVID-19 (Negar Moradian, Marjan Moallemian, Farnaz Delavari, Constantine Sedikies, Carlos A. Camargo, Jr., Pedro J. Torres, Armin Sorooshian, Saeid Paktinat Mehdiabadi, Juan J. Nieto, Stephane Bordas, Hamid Ahmadieh, Mohammad Abdollahi, Michael R. Hamblin, Frank W. Sellke, Jack Cuzick, Bozkurt Biykem, Michael Schreiber, Babak Eshrati, Georg Perry, Ali Montazeri, Ali Akbar Saboury, Roya Kelishadi, Amirhossein Sahebkar, Ali A. Moosavi-Movahed, Hassan Vatandoost, Mofid Gorji-Bandpy, Bahram Mobasher, Nima Rezaei) -- Chapter 53. Health and Art (HEART): Integrating Science and Art to Fight COVID-19 (Nima Rezaei, Aida Vahed, Heliya Ziaei, Negin Bashari, Saina Adiban Afkham, Fatemeh Bahrami, Sara Bakhshi, Alireza Ghanadan, Atlasi Ghanadan, Nastaran Hosseini, Pariya Kafi, Reihaneh Khalilianfard, Kawthar Mohammed, Sepideh Sargoli, Kosar Tavasoli, Mahya Zare, Amene Saghazadeh).

Description / Table of Contents: Chapter 1. The fossil record of parasitism: Its extent and taphonomic constraints -- Chapter 2. Importance of data on fossil symbioses for parasite-host evolution -- Chapter 3. Biodiversity and host-parasite (co)extinction -- Chapter 4. Evolutionary history of colonial organisms as hosts and parasites -- Chapter 5. Crustaceans as hosts of parasites throughout the Phanerozoic -- Chapter 6. Trilobites as hosts for parasites: From paleopathologies to ethiologies -- Chapter 7. Evolutionary history of cephalopod pathologies linked with parasitism -- Chapter 8. Bivalve Mollusks as Hosts in the Fossil Record -- Chapter 9. Parasitism of Paleozoic Crinoids and Related Stalked Echinoderms: Paleopathology, Ichnology, Co-Evolution, and Evolutionary Paleoecology -- Chapter 10. Deep origin of parasitic disease in vertebrates -- Chapter 11. Gastrointestinal parasites of ancient non-human vertebrates: Evidence from coprolites and other materials -- Chapter 12. Blood to Molecules: The Fossil Record of Blood and its Constituents -- Chapter 13. The Molecular Clock as a Tool for Understanding Host-Parasite Evolution -- Chapter 14. Horizontal Transfer of Transposons as Genomic Fossils of Host-Parasite Interactions.

Description / Table of Contents: Chapter 1. Parasites of Fossil Vertebrates: What We Know and What can We Expect from the Fossil Record? -- Chapter 2. Fossil Record of Viruses, Parasitic Bacteria and Parasitic Protozoa -- Chapter 3. Fungi as Parasites: A Conspectus of the Fossil Record -- Chapter 4: Evolution, Origins and Diversification of Parasitic Cnidarians -- Chapter 5. Evolutionary History of Bivalves as Parasites -- Chapter 6. Gastropods as Parasites and Carnivorous Grazers – A Major Guild in Marine Ecosystems -- Chapter 7: Fossil Constraints on the Timescale of Parasitic Helminth Evolution -- Chapter8. Thorny-headed Worms (Acanthocephala): Jaw-less Members of Jaw-bearing Worms that Parasitize Jawed Arthropods and Jaw-bearing Vertebrates -- Chapter 9. Chelicerates as Parasites -- Chapter 10. Evolutionary History of Crustaceans as Parasites -- Chapter 11. The History of Insect Parasitism and the Mid-Mesozoic Parasitoid Revolution.

Description / Table of Contents: 1. Introduction to COVID-19 -- 2. Medicinal plants as COVID-19 remedy -- 3. Traditional Chinese Medicines as possibly remedy Against SARS- CoV-2 -- 4. Plant natural products against COVID-19 -- 5. Foods as first defense against COVID-19 -- 6. Drugs for the treatment of COVID-19 -- 7. COVID-19 pandemic and vaccines -- 8. Recent updates in vaccine development against COVID-19 -- 9. Recent developments in therapeutic approaches against COVID-19.

Description / Table of Contents: 1. Introduction and history -- 2. Basic principles of drug delivery and dosing -- 3. Sulfonamides -- 4. Penicillins -- 5. Cephalosporins -- 6. Monobactams: Aztreonam -- 7. Carbapenems -- 8. Glycopeptides and other agents used to treat gram-positive cocci -- 9. Vancomycin: New Area-under-the-curve-based therapeutic monitoring -- 10. Aminoglycosides -- 11. Macrolides -- 12. Metronidazole and clindamycin -- 13. Quinolones -- 14. Tetracyclines -- 15. Pleuromutilin -- 16. Antimicrobial stewardship: evolution into the 21st century -- 17. Clinical approach to the treatment of infectious diseases -- 18. Understanding drug allergies and drug toxicities -- 19. Antibiotic-associated diarrhea -- 20. Principles of antibiotic resistance -- 21. Clinical approach to treatment of bacterial infections -- 22. Clinical approach to treatment of mycobacterial infections -- 23. Clinical approach to treatment of fungal infections -- 24. Clinical approach to treatment of viral infections -- 25. Sample cases and analyses of the use of anti-infective agents: Cases 1-15 -- Appx A. Common infectious diseases and empiric antibiotic recommendations for adult ed and inpatients at UMass Memorial Medical Center -- Appx B. Bioavailability of anti-infective agents -- Appx C. Dosage and intervals for administration of IV antimicrobials -- Appx D. Dosage and intervals for administration of oral antimicrobials -- Appx E. Important interactions with commonly-used anti-infectives -- Appx F. Oral agents that may have interactions with food -- Appx G. Drug interactions with anti-retroviral agents -- Appx H. Dosage in obesity -- Appx I. Recommendations for management of Asymptomatic Bacteriuria (ASB): 2019 update -- Appx J. Guidelines for treatment of C. difficile -- Appx K. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression -- Appx L. Guidelines for treatment of adults with community-acquired pneumonia -- Appx M. Guidelines for management of adults with hospital-acquired and ventilator-associated pneumonia -- Appx N. Guidelines for antimicrobial prophylaxis for surgery -- Appx O. Guidelines for treatment and chemoprophylaxis of influenza -- Appx P. Antimicrobial dosing in adult patients on extracorporeal membrane oxygenation (EXMO) -- Appx Q. Antimicrobial dosing in neonates.

Description / Table of Contents: Macro-, micro- and nanosensors based on biological / chemical materials -- Bactericidal, fungicidal and immunomodulating activity of nano-surfaces -- Enzymatic Tissue Biotests (MAO and AChE biotests) and Bioindicators -- Is it possible to detect less than one bacterial cell? -- SERS for bacterial, virus and protein bio-sensing -- Biosensors for virus detection -- Specific immobilization of rotaviruses for atomic force microscopy with using Langmuir antibody films based on amphiphilic polyelectrolytes -- Fluorimetric and SERS sensor systems for diagnostics and monitoring of catecholamines-dependent diseases -- Enhanced sensitivity rapid tests for the detection of sepsis marker procalcitonin -- Analytical capabilities of some biosensors for the determination of drugs -- Electrochemical DNA sensors based on nanostructured polymeric materials for determination of antitumor drugs -- Variants of amperometric biosensors in the determination of some micotoxins: analytical capabilities -- New class of diagnostic systems based on polyelectrolyte microcapsules for urea detection -- Bioluminescent nano- and micro-biosensing elements for detection of organophosphorous compounds -- Nano- and microelectrochemical biosensors for determining blood glucose -- Micro-Electrochemical SMBG Biosensor Chip Design Development for Sustainable Mass Production based on the Strategic Platform Patent Map -- Biological Fuel Cells: Applications in Health Service and Ecology -- Recent Trends in Fabrication and Applications of Wearable Bioelectronics for Early-Stage Disease Monitoring and Diagnosis -- Self-powered biosensors in medicine and ecology -- Self-powered implantable biosensors – a review of recent advancements and future perspectives.

Description / Table of Contents: 1. Microbes and infectious diseases -- 2. Acne -- 3. Skin abscesses (boils) -- 4. Dandruff -- 5. Fungal nail infections -- 6. Fungal infections of the skin -- 7. Chickenpox -- 8. Shingles -- 9. Common warts -- 10. The common cold -- 11. Influenza -- 12. Sore throat -- 13. Coronavirus disease-2019 -- 14. Acute sinusitis -- 15. Chronic sinusitis -- 16. Otitis media (middle ear infection) -- 17. Otitis externa (swimmers ear) -- 18. Acute bronchitis (chest cold) -- 19. Conjunctivitis (pink eye) -- 20. Tooth decay (caries) -- 21. Gum disease -- 22. Bad breath -- 23. Oral thrush -- 24. Oral herpes -- 25. Cystitis (lower urinary tract infection) -- 26. Vaginitis -- 27. Chlamydia -- 28. Gonorrhoea -- 29. Genital herpes -- 30. Genital warts -- 31. Syphilis -- 32. Gastroenteritis due to Campylobacter -- 33. Gastroenteritis due to Salmonella -- 34. Gastroenteritis due to Clostridium perfringens -- 35. Gastroenteritis due to Norovirus -- 36. Gastroenteritis due to Rotavirus.

Description / Table of Contents: Phages as an alternative to antibiotics -- Prevention of Dengue virus infection -- War against Respiratory Syncytial virus -- Global outbreak of Ebola virus disease and strategy to control -- A Polio virus eradication -- Influenza associated thrombotic microangiopathies -- Hepatitis delta: virological and clinical aspects -- Papilloma virus, its molecular pathway and targets -- Human metapneumovirus -- Human fatality by Zika and Chikungunya virus co-infection with prolonged viremia and viruria -- Viral peptide and membrane fusion -- Crimean Congo hemorrhagic fever – an up date -- Zika – a neutropic virus -- Ebola from emergence to epidemic -- Crimean Congo hemorrhagic fever -- Introduction of Epstein Barr virus and lymphoma -- Hepatitis B virus -- Global spread of hemorrhagic fever viruses -- Latent interferon alpha B2 treatment for hepatitis C virus -- vaccine against Crimean Congo Fever virus -- Alpha herpes virus: brief introduction and pathogenecity -- E protein inhibitor or methyl transferase inhibitor of Dengue virus -- Dengue fever again in Pakistan -- Prevalence of Epstein-Barr virus genotypes -- Future use of geospatial techniques.....analysis of Dengue virus -- Management and treatment of Dengue and Chikungunya – natural products to the rescue -- Crimean Congo fever in WHO Eastern Mediterranean region -- Dengue virus infection of primary human smooth muscle cells -- Temperature dependent transmission of potential model for Chikungunya in India -- Immune checkpoints as immune system regulators and potential biomarkers in HIV-1 infection -- The Rabies virus L protein catalyzes mRNA capping with GDP polyribonucleotidyltransferase activity -- Impact of genome changes on virulence of Enterovirus 71 -- Acquired auditory neuropathy spectrum disorder after the attack of Chikungunya -- Review on the antagonist Ebola: a prophylactic approach -- Hijacking the host immune cells by Dengue virus -- Pandemic influenza preparedness in the WHO African regions -- The genetics of post-polio syndrome – an overview -- Zika virus disease in India -- Merkel cell Polyoma virus responsible for Merkel cell carcinoma -- Fitness differences of hepatitis virus genotype D and F -- HCV inhibitors: significance of non-structural polyprotein -- Duel threat: clinical concerns in HIV-HBV-co-infection -- Deciphering emerging Zika and Dengue viral epidemics: implications for global maternal-child health burden -- From Dengue to Zika: the wide spread of mosquito-borne arboviruses -- Causes of high polio vaccine dropout among Pakistani children.

Description / Table of Contents: Assessment of liver disease severity -- Hepatitis C and autoimmunity -- Extrahepatic manifestations -- Treatment indications and pretreatment assessment -- Available agents - contraindications and potential drug-drug interactions -- Current management of patients with HCV genotype 1 -- Current management of patients with HCV genotype 2 -- Current management of patients with HCV genotype 3 -- Current management of patients with HCV genotype 4 -- Current management of patients with HCV genotype 5 or 6 -- The role of RAVs in the current management of HCV -- Management of patients with HCV decompensated cirrhosis -- Management of patients with acute hepatitis C -- Management of transplant patients -- Management of immune complex-mediated manifestations of HCV -- Management of patients with co-infections (HBV, HIV) -- Management of patients under hemodialysis.-Management of active drug addicts or patients on maintenance substitution -- Management of patients with hemoglobinopathies or bleeding disorders -- Follow-up during and after treatment.

Description / Table of Contents: Chapter 1. Why the Spike protein is relevant for COVID19 therapeutics -- Chapter 2. SARS-CoV-2 variants -- Chapter 3. Conclusion.

Description / Table of Contents: 1. Overview of the impact of protein interfacial instability on the development of biologic products -- 2. Protein adsorption at a gas-aqueous interface -- 3. Interfacial behaviors of proteins -- 4. Interfacial stresses during drug substance purification processes -- 5. Evaluation of interfacial stress during drug product development -- 6.Relating interfacial shear and dilatations stress-es to protein aggregation in mAbs -- 7. Analytical techniques for evaluating protein instability at interfaces -- 8. Analysis of aggregates and particles -- 9. Protein interfacial instability of mixing and lyophilization during drug product manufacturing process scale-up and tech transfer -- 10. Excipients: Characterization, purpose, and selection -- 11. Interfacial stress and proteins prepared in the solid state -- 12. Interfaces in protein drug delivery: device concern -- 13. Future perspectives. .

Description / Table of Contents: 1. Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement -- 2. Prevalence of COVID-19 and the Continued Citizen-based Control in Japan -- 3. COVID-19 Pandemicin Brazil: History, Characteristics, and Evolution -- 4. The Experiences of Recovered COVID-19 Patients in Baqiyatallah Hospital: A Qualitative Study -- 5. Age-specific Differences in the Severity of COVID-19 Between Children and Adults: Reality and Reasons -- 6. Sex differences and COVID-19 -- 7. Intestinal Microbiota in the Sars-Cov2 Infection: What is known? -- 8. SARS-CoV-2 Infection and the Kidneys: an Evolving Picture -- 9. Cutaneous Manifestations of COVID-19: Early Diagnosis and Prognostic Information -- 10. How do we Manage Breastfeeding during the COVID-19 Pandemic? -- 11. Deep Learning Analysis in Prediction of COVID-19 Infection Status using Chest CT Scan Features -- 12. Using Ozone Therapy as an Option for Treatment of COVID-19 Patients: A Scoping Review -- 13. COVID-19, Coenzyme Q10 and Selenium -- 14. Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19) -- 15. Cinnamon: A Promising Natural Product against COVID-19 -- 16. Curcumin and Piperine in COVID-19: a Promising Duo to the Rescue -- 17. Association of in-hospital use of statins, aspirin and renin-angiotensin-aldosterone inhibitors with mortality and ICU admission due to COVID-19A -- 18. The Worldwide Effort to Develop Vaccines for COVID-19.

Description / Table of Contents: Introduction -- Composition of Microbiomes -- Dynamics of Microbiomes -- Holistic Fitness: Microbiomes are Part of the Holobiont`s Fitness -- Transmission of Hologenomes Between Generations: Mothers Matter Most -- Eukaryotic Microorganisms are Part of Holobionts -- Viruses are Part of the Holobiont`s Fitness and Evolution -- Genetic Variation in Holobionts -- Evolution of Holobionts: The Hologenome Concept -- Microbiomes in Medicine and Agriculture -- Microbiomes: Some Philosophical and Sociological Implications.

Description / Table of Contents: Chapter 1. Introduction to Veterinary Vaccines -- Chapter 2. "What is Required to Develop a Viral Vector Vaccine: Key Components of Vaccine-Induced Immune Responses" -- Chapter 3. Viruses and the evolution of viral vectors -- Chapter 4. The role of adjuvants in the application of viral vector vaccines -- Chapter 5. Adenovirus Vectors -- Chapter 6. Poxvirus Vectors -- Chapter 7. The Construction and Evaluation of Herpesvirus Vectors -- Chapter 8. Paramyxoviruses as Vaccine Vectors -- Chapter 9. Rhabdoviruses as vaccine vectors for veterinary pathogens -- Chapter 10. Coronaviruses as Vaccine Vector for Veterinary Pathogens -- Chapter 11. Alphavirus-Based Vaccines -- Chapter 12. Manufacturing and Control of Viral Vectored Vaccines: Challenges -- Chapter 13. Regulatory strategies and factors affecting veterinary viral vector development -- Chapter 14. "Emerging Viral Vectored Technology Future potential of capripoxvirus and African swine fever virus as viral vectors". .

Description / Table of Contents: Introduction -- Historical Aspects -- Virology -- HCV Genotypes and HCV Evolution -- Pathogenesis and Histopathology -- Laboratory Diagnosis -- Epidemiology -- Transmission -- PWIDs and other key populations -- Natural history -- Modeling of natural history -- Surveillance -- Burden of disease -- Molecular epidemiology -- Prevention -- Health Care Associated Hepatitis -- Harm reduction in PWIDs -- Sexually, vertical and unusual ways of transmission -- Secondary prevention and screening -- Treatment-as-Prevention.

Description / Table of Contents: PART I - Introduction -- Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist -- PART II - Innovation in the Discovery of Novel Therapeutic Approaches -- Drug Discovery in CNS: Finding a Target for What? -- Neurogenomics with Application to Schizophrenia and Other Major Neuropsychiatric Diseases with Complex Heredity -- Epigenetics in Drug Discovery: Achievements and Challenges -- Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation -- Safety and Drug Metabolism: Toward NCE and First in Human -- The Various Forms of Non-invasive Brain Stimulation and Their Clinical Relevance -- Is Non-invasive Brain Stimulation the Low-Hanging Fruit? -- PART III - Translational Medicine and Technology -- Electrophysiology: From Molecule to Cognition, from Animal to Human -- MRI in CNS Drug Development -- Positron Emission Tomography in Drug Development -- Application of Cognitive Test Outcomes for Clinical Drug Development -- Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information -- A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development -- PART IV - Clinical Development and Regulatory Approval -- The Special Challenges of Developing CNS Drugs -- Phase 1 Clinical Trials in Psychopharmacology -- Early Development of Erenumab for Migraine Prophylaxis -- Microdosing Psychedelics as a Promising New Pharmacotherapeutic -- Partnering with the FDA.

Description / Table of Contents: Introduction and History of Ophthalmic Product Development -- Ocular Surface Anatomy and Physiology: Impact on Product Development -- Anatomy and Physiology of the Anterior Chamber – Impact on Product Development -- Back of the eye anatomy & physiology – Impact on product development -- Physicochemical and Biological Fundamentals for Drug Delivery to the Eye -- Topical Ophthalmic Dosage Form Development – Key Components and Critical Quality Attributes -- Intra-ocular Injectable Dosage Form Development -- Microbiological Considerations for Ophthalmic Products – Sterility, Endotoxin Limits and Preservatives -- Packaging Development – Multi-dose container closure for preservative free products, extractable/leachables from packaging, new technologies -- Liquid ophthalmic drug products – physicochemical properties, formulations and manufacturing considerations -- Emulsions for topical eye delivery: state of the art and future perspectives -- Emulsions for topical eye delivery: state of the art and future perspectives -- Microparticle Products For The Eye - preformulation, formulation, and manufacturing considerations -- NANOPARTICLE PRODUCTS FOR THE EYE: preformulation, formulation and manufacturing considerations -- Advanced Hydrogel Formulations for the Eye -- Ophthalmic Product Development for Biologics -- Implantable Devices to Treat Ophthalmic Conditions –Drug Delivery Systems -- Development of Artificial Tears Products for Ocular Conditions -- Approval of Topical Ophthalmic Generic Products in the US – Simple to Complex Dosage Forms and Establishing Equivalency -- The development and commercialization of sustained-release ocular drug delivery technologies -- Manufacturing considerations and challenges for AAV Ocular Gene Therapy -- Transcorneal Kinetics of Topical Drugs and Nanoparticles.

Description / Table of Contents: Preface -- Liposome Formulations as Adjuvants for Vaccines -- Polymeric nanoparticle-based vaccine adjuvants and delivery vehicles -- Virus-like particle vaccines against respiratory viruses and protozoan parasites -- Protein and Peptide Nanocluster Vaccines.

Description / Table of Contents: Chapter 1. Introduction -- Chapter 2. Spatial Epidemiology: Challenges and Methods in COVID-19 Research -- Chapter 3. Disease Ecology -- Chapter 4. COVID-19 and the Political Ecology of Global Food and Health Systems -- Chapter 5. Setting a Death Trap: International Political Economy, COVID-19 Responses, and the Plight of Central American Migrants -- Chapter 6. Emergent Global Pandemic Risks, Complex Systems, and Population Health -- Chapter 7. Eight Centuries of Epidemic and Pandemic Control -- Chapter 8. Humanism and Social Constructionism -- Chapter 9. Mapping the Post-Structural Geographies of COVID-19 -- Chapter 10. Non-Representational Approaches to COVID-19 -- Chapter 11. How to Have Theory in a Pandemic: A Critical Reflection on the Discourses of COVID-19 -- Chapter 12. Health Service Capacities, Responses, and Practice -- Chapter 13. Informal Care: The Forgotten Frontlines of COVID-19 -- Chapter 14. Resilience, Risk, and Policymaking -- Chapter 15. Managing Internationally Mobile Bodies in a World on Hold: Migration, Tourism, and Biological Citizenship in the Context of COVID-19 -- Chapter 16. Mobility is Dead: Post-pandemic Planning as an Opportunity to Prioritize Sustainability and Accessibility -- Chapter 17. Media and Information in Times of Crisis: The Case of the COVID-19 Infodemic -- Chapter 18. The (Social Distanced) Circle of Family, Friends, and Allies: How COVID-19 is Re-shaping Social Capital and New Opportunities for Research -- Chapter 19. The Syndemic Pandemic: COVID-19 and Social Inequality -- Chapter 20. Maintaining Wellbeing During and After COVID-19 -- Chapter 21. Pandemic Geographies of Physical Activity -- Chapter 22. Surveillance, Control, and Containment (Biopolitics) -- Chapter 23. Contradictory and Compounding: The Social Implications of COVID-19 -- Chapter 24. Geographical Metaphors in Everyday Life -- Chapter 25. Vaccine Geopolitics During COVID-19: How Pandemics Thicken Borders, Exacerbate Violence, and Deepen Existing Fault Lines -- Chapter 26. Geographies of Digital Storytelling: Care and Harm in a Pandemic -- Chapter 27. Animal Geographies in a Pandemic -- Chapter 28. Environment and COVID-19: Unpacking the Links -- Chapter 29. Home in the Context of COVID-19 -- Chapter 30. Death, Devastation, and Failure in Long-term care: The Need for a Geographical Re-engagement with the Sector -- Chapter 31. Re-figuring Public Spaces? -- Chapter 32. Consumer Spaces -- Chapter 33. The Place, Labour, and Networks of Transportation during COVID-19 -- Chapter 34. COVID-19: Pandemic on an Urban Planet -- Chapter 35. Geographies of the Rural and the COVID-19 Pandemic -- Chapter 36. Global Spaces: COVID-19 and the Reconfiguring of Global Health -- Chapter 37. Why Green and Blue Spaces Matter More than Ever -- Chapter 38. COVID-19 in the Developing World: Curse or Blessing? -- Chapter 39. Art Spaces -- Chapter 40. Practicing Self-determination to Protect Indigenous Health in COVID-19: Lessons for this Pandemic and Similar Futures -- Chapter 41. #thenewnormal and the Pathological: Rethinking Human-Virus Relations during the COVID-19 Pandemic -- Chapter 42. Older People -- Chapter 43. Children and Families -- Chapter 44. Race, Ethnicity, and COVID-19: The Persistence of Black-White Disparities in the United States -- Chapter 45. Understanding the Importance of Gender for COVID-19 -- Chapter 46. People with Disabilities -- Chapter 47. Participatory Research by/for the Precariously Housed in a time of COVID-19 -- Chapter 48. Mental-ill Health and Anxious Pandemic Geographies -- Chapter 49. COVID-19 and Health Professionals: Recommitting to a Global Health Agenda -- Chapter 50. Labor Geography, Racial Capitalism, and the Pandemic Portal -- Chapter 51. Geographies of (Domestic) Alcohol Consumption -- Chapter 52. Public Geographies in a Post-COVID-19 World -- Chapter 53. Textures of an Epidemic: On the Necessity of Qualitative Methods in Making Better Pandemic Futures -- Chapter 54. Counting COVID: quantitative geographical approaches to COVID-19 -- Chapter 55.GIS and Spatial Representations: Challenges and Missteps -- Chapter 56. New Forms of Data, New Forms of Opportunities to Monitor and Tackle a Pandemic -- Chapter 57. Knowledge Translation and COVID-19 -- Chapter 58. Examining Geographical Visualizations of COVID-19.

Description / Table of Contents: Successful Vaccines -- Immunogenicity and Immunodominance in Antibody Responses -- Immunogen Design -- Adjuvants -- Tools to screen vaccines -- Targeting glycans on human pathogens for vaccine design -- BnAbs and highly antigenically variable pathogens.

Description / Table of Contents: Rabies Life Cycle, Transmission and Pathogenesis -- History of Rabies and Rabies Vaccines -- Rabies vaccines for wildlife -- Human Rabies Vaccines -- Rabies vaccines, prophylactic, Peru -- Rabies Prevention in Asia: Institutionalizing Implementation Capacities -- Passive Immunity in Rabies Prophylaxis -- Rabies Little Virus Against Powerful Innate Immunity -- Novel Rabies Vaccines -- Assessing the potency of inactivated veterinary vaccines and oral live vaccines against rabies -- WHO Perspective on Rabies.

Description / Table of Contents: Introduction -- Project Management Concepts -- Theory of Constraints.-Project Management Process -- Risk Evaluation Process -- Project Plan Implementation -- Financial Project Management -- Project Outsourcing -- List of Abbreviations -- Index. .

Description / Table of Contents: Chapter 1. Introduction: Trends and developments in the pharmaceutical and life sciences industry -- Chapter 2. Relevance of instruments for measurements of Quality of Life in the AMNOG Context -- Chapter 3. The quality management system for R&D project and portfolio management in a pharmaceutical company -- Chapter 4. Brexit and Its Impact on Pharmaceutical Law - Implications for global pharma companies -- Chapter 5. Implementation of Measurable and Sustainable Actions to Improve Employee’s Engagement and Business Performance - Global Medical Clinical & Regulatory Affairs (GMCRA) – A Role Model at Fresenius Kabi -- Chapter 6. Leadership Models and Work Behavior: An Empirical Analysis of Consequences of Authentic and Transformational Leadership -- Chapter 7. Alliance Management at Merck - Establishing an operational 100-day plan for alliance launches and management.

Description / Table of Contents: Introduction -- Chemistry and Thermodynamics -- Solid State -- Dynamics -- Quality by Design -- Pharmacokinetics and Pharmacodynamics -- Poputaltion Biology -- Machine Learning.

Description / Table of Contents: Introduction -- PART 1: How Drugs are Discovered and Developed in the Pharmaceutical Industry -- Introduction to Drugs and Drug Targets -- Background to chemistry of small and large molecules -- Laying the foundations- Drug discovery from antiquity to the twenty first century -- Part II-The drug development pipeline – discovery to testing in humans -- Drug discovery pipeline overview -- Target discovery -- Medicinal chemistry -- Biotherapeutics -- Screening for hits -- Process chemistry and formulation -- Preclinical development -- Part III-The drug development pipeline – clinical trials to marketing authorisation -- Clinical trials -- Regulatory affairs and marketing approval -- Diagnostics and personalized medicine -- Putting it All Together: a drug development case history -- Part IV- The Global Pharmaceuticals Business -- Commercial aspects of drug development -- Challenges and responses -- Part V - Professional Interactions with the Drug Discovery Industry.-Professional Interactions with the Drug Discovery Industry: Technology Transfer Executives -- Recruitment Executives -- Pharmaceutical translators and Interpreters.

Description / Table of Contents: Section I Background -- Introduction to Nanomedicine -- Characterization of Nanoparticles -- Section II Drugs and Biologics Encapsulated in Nanoparticles -- Routes of Delivery -- Small molecule Delivery -- Peptide and Protein Delivery -- Gene Delivery (siRNA/CRISPR) -- Phage Therapy -- Section III Diseases -- Non-infectious Diseases -- Infectious Diseases -- Cancer -- Section IV Host Interactions with Nanoparticles -- Interaction of Nanoparticles with Epithelial and Immune Cells -- Toxicity of Nanoparticles to the Host -- Nanoparticle Pharmacokinetics and Pharmacodynamics -- Section V MIscellanous -- Nanoparticles as Theranostics -- Regulatory Perspectives -- Manufacturing Scale-up of Nanoparticles.

Description / Table of Contents: Preface -- 01. Nanotechnology applications for natural products delivery -- 02. Nanotechnology-inspired bionanosystems for valorization of natural origin extracts -- 03. Nanocarriers as tools for delivery of nature derived compounds and extracts with therapeutic activity -- 04. Nanoemulsions as optimized vehicles for essential oils -- 05. Lipid Nanoarchitectonics for Natural Products Delivery in Cancer Therapy -- 06. Inorganic particles for delivering natural products -- 07. Nanotechnology based targeting strategies for the delivery of camptothecin.

Description / Table of Contents: Ch-01 Targeting ROS-mediated Crosstalk between Autophagy and Apoptosis in Cancer -- Ch-02 Micronutrients that Affect Immunosenescence -- Ch-03 Bioactive Lipids in Age-Related Disorders -- Ch-04 Effect of Short Chain Fatty Acids on Age-Related Disorders -- Ch-05 The Effects of Parabiosis on Aging and Age-related Diseases -- Ch-06 Skeletal Muscle Aging Atrophy: Assessment and Exercise-Based Treatment -- Ch-07 Polyphenols as an Effective Therapeutic Intervention Against Cognitive Decline during Normal and Pathological Brain Aging -- Ch-08 Early Diagnosis and Targeted Treatment Strategy for Improved Therapeutic Outcomes in Alzheimer’s Disease -- Ch-09 Resetting the Aging Clock: Implications for Managing Age-Related Diseases -- Ch-10 The Challenge of Antidepressant Therapeutics in Alzheimer's Disease -- Ch-11 Anxiolytic Terpenoids and Aromatherapy for Anxiety and Depression -- Ch-12 The Role of Nutrition in Attenuating Age-Related Skeletal Muscle Atrophy -- Ch-13 The Use of Metformin to Increase the Human Healthspan.

Description / Table of Contents: Basic Principles of Continuous Manufacturing -- Continuous Reactors for Pharmaceutical Manufacturing -- Understanding Residence Time, RTD, and Impact of Surge Vessels -- Practical Considerations for Continuous Drug Substance Manufacturing -- Continuous Crystallization: Equipment and Operation -- Continuous Feeding-Blending in Pharmaceutical Continuous Manufacturing -- Recent Progress in Roll Compaction Process Development for Pharmaceutical Solid Dosage Form Manufacture -- Continuous wet granulation processes -- Fluidized Bed Drying -- Statistical Methods in Quality by Design and Process Analytical Technologies for continuous processes to enable real-time release -- Active Process Control in Pharmaceutical Continuous Manufacturing-The Quality by Control (QbC) Paradigm -- Real-time Optimization in Pharmaceutical Manufacturing -- Safety Guidelines for Continuous Chemistry Experimental Work in the Laboratory -- Evaluating the Busieness/Supply Chain Benefits of Continuous Processing in Pharmaceuticals -- Regulatory Considerations for Continuous Manufacturing.

Description / Table of Contents: Preface -- Part I: Fundamentals of Systemic Delivery -- Anti-aging medicine: new concepts and intervention development,- Roles of systemic delivery in the development of anti-aging therapies -- Pharmacokinetics and pharmacodynamics in drug delivery -- Physiological, biochemical, and chemical barriers to systemic delivery -- Partt II: Development of Delivery Technologies for Systemic Delivery -- Use of prodrugs for systemic delivery in anti-aging medicine -- Use of physical methods for systemic delivery in anti-aging medicine -- Use of viral systems for systemic delivery in anti-aging medicine -- Use of non-viral biological systems for systemic delivery in anti-aging medicine -- Use of lipid-based systems for systemic delivery in anti-aging medicine -- Use of polymeric systems for systemic delivery in anti-aging medicine -- Use of inorganic nanoparticles for systemic delivery in anti-aging medicine -- Part III: Practical Considerations in Intervention Execution -- Strategies in carrier design to enhance systemic delivery -- Characterization techniques for studying the properties of the carriers -- In vivo assessment of the efficiency of systemic delivery in anti-aging medicine -- Selection of administration routes for systemic delivery in anti-aging medicine -- Intellectual property and regulatory issues in drug delivery research -- Index.

Description / Table of Contents: Preface -- 1. Pharmaceutical technology for improving the of bioavailability of natural products -- 2. Solubility Enhancement Techniques for Natural Product Delivery -- 3. Delivery of natural products using polymeric particles for cancer chemotherapeutics -- 4. Chemistry, pharmacology and therapeutic delivery of major tea constituents -- 5. Current approaches and recent advances in Galantamine Delivery for Alzheimer’s -- 6. Overview of Paclitaxel Delivery Systems -- 7. Phytosomes as an emerging nanotechnology for herbal drug delivery -- 8. Albumin as natural versatile drug carrier and various diseases treatment.